



*Presented by*



---

## Daily COVID 19 Opportunities Update

April 9, 2020

---

### Table of Contents

#### Health Systems Capacity Building (including telemedicine)

##### Department of Agriculture

Distance Learning & Telemedicine Grants

##### Department of Defense

Department of the Air Force

- Commercial Solution Opening - CSO\_COVID\_19 Response

##### Department of Health and Human Services

Administration for Children & Families

- Family Violence Prevention and Services Discretionary Grants: Specialized Services for Abused Parents and Their Children (Demonstration Projects) Administration for Community Living

Agency For Healthcare Research and Quality (AHRQ)

- Flexibilities Available to AHRQ Recipients and Applicants Directly Impacted by the Novel Coronavirus (COVID-19) Due to Loss of Operations
- Agency for Health Care Research and Quality - Competitive Revision Supplements to Existing AHRQ Grants and Cooperative Agreements to Evaluate Health System and Healthcare Professional Responsiveness to COVID-19 (Supplement - Clinical Trial Optional) \*\*
- Announcement to Support Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19 \*\*

Centers for Disease Control

- Tribal Public Health Capacity Building and Quality Improvement Umbrella Cooperative Agreement

- Supporting Tribal Public Health Capacity in Coronavirus Preparedness and Response

Health Resources and Services Administration

- Telehealth Network Grant Program

Substance Abuse and Mental Health Services Administration

- Emergency Grants to Address Mental and Substance Use Disorders During COVID-19

Department of Health and Human Services

Administration for Community Living

- ADRC/No Wrong Door System Funding Opportunity: Critical Relief Funds for COVID-19 Pandemic Response

Department of Homeland Security

FEMA

- Fiscal Year (FY) 2019 Staffing for Adequate Fire and Emergency Response (SAFER)

Federal Communication Commission

- Guidance on the COVID-19 Telehealth Program Application Process

**Manufacturing/Technology Research Opportunities**

Department of Commerce

National Institute of Standards and Technology

- NIST Manufacturing USA National Emergency Assistance Program

Department of Defense

- Department of the Army - Medical Technology Enterprise Consortium (MTEC) - National Emergency Telecritical Care Network (NETCCN) Project for Coronavirus

Department of the Air Force

- Commercial Solution Opening - CSO\_COVID\_19 Response

Department of Health and Human Services

Office of the National Coordinator for Health Information Technology (ONC)

- Tools and Resources for the Health IT and Clinical Community

**Medical Research Opportunities**

Department of Defense

- Department of the Air Force - Commercial Solution Opening - CSO\_COVID\_19 Response
- Newton Award for Transformative Ideas during the COVID-19 Pandemic

- Department of the Army - Medical CBRN Defense Consortium (MCDC) - Medical CBRN Defense Consortium (MCDC) Other Transaction Agreement (OTA) Request for Information (RFI) - CoV Pandemic Response
- Department of the Army - Medical Technology Enterprise Consortium (MTEC) - National Emergency Telecritical Care Network (NETCCN) Project for Coronavirus
- Department of the Army - Defense Biological Product Assurance Office's (DBPAO) - Development of Lateral Flow Immunoassays (LFI) for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
- Department of the Army – USAMRAA - CDMRP PRMRP Technology/Therapeutic Development Award for Emerging Viral Diseases and Respiratory Health \*\*
- Department of the Army – USAMRAA - USAMRAA - CDMRP PRMRP Investigator-Initiated Research Award for Emerging Viral Diseases and Respiratory Health\*\*
- Department of the Army – USAMRAA - CDMRP PRMRP Clinical Trial Award for Emerging Viral Diseases and Respiratory Health\*\*

#### Department of Health and Human Services

##### National Institutes of Health

- National Institute on Minority Health and Health Disparities (NIMHD) - Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities\*\*
- National Institute of Mental Health (NIMH) - Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus\*\*
- National Cancer Institute (NCI) - Notice of Special Interest (NOSI): National Cancer Institute Announcement regarding Availability of Competitive Revision SBIR/STTR Supplements on Coronavirus Disease 2019 (COVID-19) \*\*
- National Institute on Deafness and Other Communication Disorders (NIDCD) - Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) \*\*
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) - Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIDDK\*\*
- National Human Genome Research Institute - Notice of NHGRI's Participation in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)"

- National Institute of Allergy and Infectious Diseases (NIAID) - Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)
- National Institute of Allergy and Infectious Diseases (NIAID) - Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)
- National Center for Advancing Translational Sciences - Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus\*\*
- National Center for Advancing Translational Sciences Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus \*\*
- National Center for Advancing Translational Sciences - Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need
- National Center for Advancing Translational Sciences - Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19)
- National Institute of General Medical Sciences - Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2
- Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)
- National Heart, Lung, and Blood Institute - Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)
- National Institute on Drug Abuse - Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus
- Office of Assistant Secretary for Preparedness and Response - Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
- Office of Assistant Secretary for Preparedness and Response - BARDA's Division of Research, Innovation & Ventures (DRIVE) Easy Broad Agency Announcement

- Office of Assistant Secretary for Preparedness and Response - REQUEST A USG CORONAWATCH MEETING

### **Medical Supplies, Medicine, Services and Equipment**

#### **Department of Defense**

- Department of the Air Force - Commercial Solution Opening - CSO\_COVID\_19 Response
- Department of the Army - State of Minnesota - Medical PPE for COVID 19
- Department of the Navy - Medical Supplies and Personal Protective Equipment: COVID 19 Response
- National Geospatial-Intelligence Agency (NGA) - COVID 19 - Seeking potential sources for Surgical Masks and Sanitizing Wipes
- Defense Logistics Agency - Request for Information pertaining to Medical PPE in response to COVID-19 \*\*

#### **Department of Health and Human Services**

- Office of Assistant Secretary for Preparedness and Response - Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
- Office of the Assistant Secretary for Financial Resources (ASFR) - COVID-19 Response: Supplies and Services
- Food and Drug Administration - Emergency Use Authorization Declaration

#### **Department of Homeland Security**

- Federal Emergency Management Agency - COVID-19 PPE and Medical Supplies
- Federal Emergency Management Agency - RFI FEMA REGION VI COVID-19 PERSONAL PROTECTIVE EQUIPMENT

#### **Department of Veterans Affairs**

- Decontamination Tents & A/C Units
- 6515--COVID-19 Request for Information Suitable Substitutions for VISN Items - GLOVE, EXAM, NITRILE - RFI

### **Workforce and Health Systems Research**

#### **Department of Health and Human Services**

- Agency for Healthcare Research and Quality Notice of Intent: New Funding Opportunity Announcement to Support Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19

- Agency for Healthcare Research and Quality - Notice of Intent: Revision Supplements to Existing AHRQ Grants and Cooperative Agreements to Address Health System Responsiveness to COVID-19
- National Institute of Environmental Health Sciences - Notice of Special Interest: NIEHS Worker Training Program Coronavirus and Infectious Disease Response Training (Admin Supp Clinical Trial Not Allowed)

### Other Relevant Notices

#### Department of Defense

- Defense Logistics Agency - Reporting Coronavirus Impacts To Defense Logistics Agency (DLA)

#### Department of Education

Allocations for Section 18004(a)(1) of the CARES Act \*\*

#### Department of Health and Human Services

- Centers for Disease Control - COVID-19 Award Details For Emergency Supplemental Appropriation Funding
- Centers for Medicare & Medicaid Services - Medicare and Medicaid Programs; Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency – Rule
- Food and Drug Administration - Process for Making Available Guidance Documents Related to Coronavirus Disease 2019
- National Institutes of Health - NIH Late Application Policy Due to Public Health Emergency for United States for 2019 Novel Coronavirus (COVID-19)

#### Department of Housing and Urban Affairs

- CPD PROGRAM FORMULA ALLOCATIONS AND CARES ACT SUPPLEMENTAL FUNDING FOR FY 2020

#### National Endowment for the Arts

- NEA Coronavirus Aid, Relief, and Economic Security (CARES) Act, FY2020

#### National Science Foundation

Impact on Existing Deadline Dates (COVID-19)

**\*\* New Opportunity since previous day.**

---

## **Health Systems Capacity Building (including telehealth)**

### **Department of Agriculture - Distance Learning & Telemedicine Grants**

**Application Due Date:** April 14, 2020 through July 13, 2020  
**Expected Number of Awards:**  
**Estimated Total Program Funding:** \$27,000,000  
**Award Ceiling:** \$1,000,000  
**Award Floor:** \$50,000  
**Funding Opportunity Number:** HHS-2020-ACL-CIP-NWIG-0431

*Purpose: The Distance Learning and Telemedicine program helps rural communities use the unique capabilities of telecommunications to connect to each other and to the world, overcoming the effects of remoteness and low population density. For example, this program can link teachers and medical service providers in one area to students and patients in another.*

*Grant funds may be used for:*

*Acquisition of eligible capital assets, such as:*

*Broadband transmission facilities*

*Audio, video and interactive video equipment*

*Terminal and data terminal equipment*

*Computer hardware, network components and software*

*Inside wiring and similar infrastructure that further DLT services*

*Acquisition of instructional programming that is a capital asset*

*Acquisition of technical assistance and instruction for using eligible equipment*

<https://www.usda.gov/media/press-releases/2020/04/03/usda-announces-second-application-window-distance-learning-and>

### **Department of Defense – Department of the Air Force – Commercial Solution Opening - CSO\_COVID\_19 Response**

**Proposal Due Date:** September 30, 2020  
**Expected Number of Awards:**  
**Estimated Total Program Funding:**  
**Award Ceiling:**  
**Award Floor:**  
**Funding Opportunity Number:** FA300220S0002

*Purpose: The Department of the Air Force (DAF) has been tasked to address mission needs in response to the national crisis caused by the COVID-19 pandemic. The Air Force Senior Acquisition Executive (SAE) established the Department of the Air Force Acquisition COVID-19 Task Force (DAF ACT) across the acquisition enterprise (i) to execute all requirements from the Office of the Under Secretary of Defense*



for Acquisition and Sustainment Joint Acquisition Task Force, (JATF) and (ii) to collect and consolidate funding requests needed to recover programs from COVID-19 impacts. The DAF ACT contains four primary lines of effort (LOE's): (1) Relief for external assistance requirements; (2) Resilience for Defense Industrial Base Efforts; (3) Recovery for consolidating funding requests that minimize program impacts; and (4) Rapid for solicitation and execution of large-scale rapid small business contracts across all lines of effort.

#### MISSION FOCUS AREAS

- I. Combating the Spread (predictive analytics, next hotspot, threat to current activities, decision support, etc.)
- II. Welfare of Citizens (effects to transportation, movement of people and goods, education and development, physical training, regular HR functions, job transition, etc.)
- III. Readiness (continuing operations through the outbreak, coordinating with allies and partners, continuing long term projects, etc.)
- IV. Logistics (security and protection, supply chain protection and assessment, etc.)
- V. Industrial Base Impacts (impacts on small businesses, payments, contracts, large system programs, protection and expansion of critical assets, etc.)
- VI. Medical (telehealth, medical capacity and sustainment, medical supplies and equipment, etc.)
- VII. Other - Any solution/proposal that is not covered by the above topic areas but support the national response to the COVID-19 pandemic

**Contact:** Jessica.Steinhoff , Maj, USAF [jess.steinhoff@afwerx.af.mil](mailto:jess.steinhoff@afwerx.af.mil)

<https://beta.sam.gov/opp/f48d23af514f494f819f0c33e9f40e17/view>

#### **Department of Health and Human Services - Administration for Community Living - ADRC/No Wrong Door System Funding Opportunity: Critical Relief Funds for COVID-19**

<b>Application Due Date:</b>	<b>April 15, 2020</b>
<b>Expected Number of Awards:</b>	<b>56</b>
<b>Estimated Total Program Funding:</b>	<b>\$50,000,000</b>
<b>Award Ceiling:</b>	<b>\$3,000,000</b>
<b>Award Floor:</b>	<b>\$300,000</b>
<b>Funding Opportunity Number:</b>	<b>HHS-2020-ACL-CIP-NWIG-0431</b>

*Purpose: At an unprecedented pace, Federal and state leaders, community based organizations, and all avenues of the health care system are expending their time and resources to respond to the Coronavirus Infections Disease (COVID-19) pandemic. As a result of this crises, there is a greater need to support the capacity of the network and increase all efforts to coordinate services to overcome these new challenges. Aging and Disability Resource Centers (ADRC) through a coordinated No Wrong Door System infrastructure provide the foundation to support the most venerable populations during such crisis. This additional funding will help states across the country increase capacity and support resource*



allocation to ensure state and community level coordination to immediately respond to pressing needs related to the COVID-19 pandemic.

<https://www.grants.gov/web/grants/view-opportunity.html?opId=325893>

**Department of Health and Human Services - Administration for Children & Families - ACYF/FYSB - Family Violence Prevention and Services Discretionary Grants: Specialized Services for Abused Parents and Their Children (Demonstration Projects)**

<b>Proposal Due Date:</b>	<b>June 5, 2020</b>
<b>Expected Number of Awards:</b>	<b>26</b>
<b>Estimated Total Program Funding:</b>	<b>\$8,250,000</b>
<b>Award Ceiling:</b>	<b>\$375,000</b>
<b>Award Floor:</b>	<b>\$300,000</b>
<b>Funding Opportunity Number:</b>	<b>HHS-2020-ACF-ACYF-EV-1812</b>

*Purpose: This Forecast has been modified to update eligibility, which now includes county governments, city and township governments, Native American tribal governments (federally recognized) and Native American tribal organizations (other than Federally recognized tribal governments). The Forecast is also modified to provide additional clarification on expected grant activities and use of project funds.*

*The Family Violence Prevention and Services Discretionary Grants: Specialized Services for Abused Parents and Their Children (Demonstration Projects) will support up to 24 demonstration projects. Funded demonstration projects will focus on expanding their capacity (as family violence, domestic violence, and dating violence coalitions; local programs; tribal communities; and community-based programs) to prevent future domestic violence by addressing, in an appropriate manner, the needs of children exposed to family violence, domestic violence, or dating violence. All grantees will provide trauma-informed, developmentally appropriate and age-appropriate services, and culturally relevant and linguistically accessible services, to the victims and children relevant to the unique needs of children exposed to family violence, domestic violence, or dating violence, and potentially with co-occurring impacts of child abuse and neglect. All grantees will provide services for nonabusing parents to support those parents' roles as caregivers and their roles in responding to the social, emotional, and developmental needs of their children; and where appropriate, grantees will provide services while working with a nonabusing parent and child together.*

*According to 42 U.S.C. §10412, SSAPC grant funds shall be used: (A) to provide direct counseling, appropriate services consistent with 42 U.S.C. § 10412 (c)(2), or advocacy on behalf of victims of family violence, domestic violence, or dating violence and their children, including coordinating services with services provided by the child welfare system; (B) to provide services for nonabusing parents to support those parents' roles as caregivers and their roles in responding to the social, emotional, and developmental needs of their children; and (C) where appropriate, to provide the services described in this subsection while working with such a nonabusing parent and child together. Additionally, funds may be used: (A) to provide early childhood development and mental health services; (B) to coordinate activities with and provide technical assistance to community-based organizations serving abused victims or children exposed to domestic violence; and (C) to provide additional services and referrals to*

*services for children, including child care, transportation, educational support, respite care, supervised visitation, mobile/offsite services, or other necessary services.*

*All grantees will coordinate or provide services that are: (1) Developmentally, culturally, and linguistically appropriate for victims and children; (2) Relevant to the unique needs of children exposed to domestic violence, and potentially with co-occurring child abuse and neglect; (3) Trauma-informed, evidence-informed, and/or evidence-based; (4) Supportive of nonabusing parents in their roles of responding to the social, emotional, and developmental needs of their children; and (5) Able to enhance the bond between a nonabusing parent and child, where appropriate.*

## **Department of Health and Human Services - Agency For Healthcare Research and Quality (AHRQ) - Flexibilities Available to AHRQ Recipients and Applicants Directly Impacted by the Novel Coronavirus (COVID-19) Due to Loss of Operations**

**Proposal Due Date:**

**June 19, 2020**

**Funding Opportunity Number:**

**NOT-HS-20-010**

*Purpose: The purpose of this Notice is to alert the AHRQ grantee community of administrative flexibilities that will apply to AHRQ applicants and recipients. The Office of Management and Budget (OMB), in memorandum M-20-17, dated March 19, 2020, titled “Administrative Relief for Recipients and Applicants of Federal Financial Assistance Directly Impacted by the Novel Coronavirus (COVID-19) due to Loss of Operations” has identified several short-term administrative flexibilities that Federal awarding agencies may implement to assist recipients with managing administrative, financial management and audit requirements under the Uniform Guidance “Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards” – which are implemented in HHS regulation at 45 CFR Part 75,– without compromising Federal financial assistance accountability requirements.*

*The Agency for Healthcare Research and Quality (AHRQ) recognizes the significant effects that the HHS-declared COVID-19 national emergency is having on AHRQ-funded research and human subject studies, and we want to assure our grantee recipient community that AHRQ will be doing our part to help you continue your research. First and foremost, we are concerned about the safety and welfare of human subject participants and research staff that interact with study participants. Institutions should take all steps necessary to ensure the safety of all human participants and research staff involved in AHRQ-funded research and human subjects studies. Principal Investigators (PIs) should work with their institution’s office of sponsored programs regarding any changes that may need to be made to a study’s design and/or timeline. If it is determined that there is a request that requires AHRQ prior approval or review, an authorized institutional official should submit a formal request to the Grants Management Specialist named on the most recent Notice of Award (NOA).*

*The following flexibilities are applicable to AHRQ applicants and recipients impacted by COVID-19 due to loss of operations. At this time, these flexibilities are time-limited and will expire June 19, 2020, or*

sooner should OMB withdraw the authority. If OMB extends the flexibilities under M-20-17 beyond June 19, 2020, AHRQ will re-evaluate its implementation.

Affected entities are those that have been closed, or business activities have been hindered, due to COVID-19 precautionary measures and/or illnesses. Entities that are affected will be asked to provide documentation to AHRQ describing the effects, and how long their facility and AHRQ related research or training was and/or will be affected.

<https://grants.nih.gov/grants/guide/notice-files/NOT-HS-20-010.html>

**Department of Health and Human Services - Agency for Health Care Research and Quality - Competitive Revision Supplements to Existing AHRQ Grants and Cooperative Agreements to Evaluate Health System and Healthcare Professional Responsiveness to COVID-19 (Supplement - Clinical Trial Optional) \*\***

**Application Due Date:** FORECAST  
**Estimated Award Date:** September 30, 2020  
**Expected Number of Awards:**  
**Estimated Total Program Funding:**  
**Award Ceiling:**  
**Award Floor:**  
**Funding Opportunity Number:** PA-20-070

*Purpose: The Agency for Healthcare Research and Quality hereby notify grantees holding specific types of AHRQ research grants and cooperative agreements (R01, R03, R18, K12, U01, U18) that funds may be available for competitive revisions to meet immediate needs to help address timely health system and healthcare professional response to the COVID-19.*

<https://www.grants.gov/web/grants/view-opportunity.html?opId=326193>

**Department of Health and Human Services - Agency for Health Care Research and Quality - Announcement to Support Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19 \*\***

**Application Due Date:** FORECAST  
**Estimated Award Date:** September 30, 2020  
**Expected Number of Awards:**  
**Estimated Total Program Funding:**  
**Award Ceiling:**  
**Award Floor:**  
**Funding Opportunity Number:** PA-20-071

*Purpose: The health systems research community should prepare to submit applications to AHRQ to fund critical research focused on evaluating topics such as innovations and challenges encountered in the rapid expansion of telemedicine in response to COVID-19, effects on quality, safety, and value of health system response to COVID-19, and the role of primary care practices and professionals during the COVID-19 epidemic. AHRQ is particularly interested in understanding how digital health innovations contributed to health system and healthcare professional innovation and challenges and solutions to meeting the needs of vulnerable populations including older adults, people living with multiple chronic conditions, rural communities, and uninsured and underinsured populations.*

<https://www.grants.gov/web/grants/view-opportunity.html?opId=326194>

**Department of Health and Human Services - Centers for Disease Control - OSTLTS - Tribal Public Health Capacity Building and Quality Improvement Umbrella Cooperative Agreement**

<b>Proposal Due Date:</b>	<b>April 24, 2020</b>
<b>Expected Number of Awards:</b>	<b>25</b>
<b>Estimated Total Program Funding:</b>	<b>\$62,500,000</b>
<b>Award Ceiling:</b>	<b>\$500,000</b>
<b>Award Floor:</b>	<b>\$20,000</b>
<b>Funding Opportunity Number:</b>	<b>CDC-RFA-OT18-1803</b>

***Purpose:** CDC announces a new cooperative agreement (CoAg) for eligible federally recognized American Indian and Alaska Native (AI/AN) tribal nations and regional AI/AN tribally designated organizations to strengthen and improve the public health infrastructure and performance of tribal public health systems. The intent of this program is to assist in public health infrastructure improvement; workforce development; tribal data and information systems enhancement, including surveillance; and development and adaptation of evidence-based and evidence-informed interventions to increase the long-term sustainability of the collective tribal public health system. This program's ultimate outcomes are 1) decreased morbidity and mortality among AI/ANs; 2) advanced capacity of Indian Country to identify, respond to, and mitigate public health threats; 3) improved capacity of the workforce to deliver essential public health services; 4) increased culturally-appropriate practice-based evidence programs and policies that are effective and sustainable throughout Indian Country; and 5) improved capacity to collaboratively and strategically address AI/AN health needs and advance health equity/.. An applicant's program is expected to demonstrate measurable progress towards two or more of the following outcomes: Increased implementation of tools and processes that build operational capacity and effectiveness. Increased use of core and discipline-specific public health competencies among public health workers Improved collection, maintenance, interpretation, and dissemination of tribal health data Translation of evidence-based and evidence-informed practices into culturally appropriate public health programs, policies, and services. Development of culturally relevant public health resources and communication tools. Established multi-sector partnerships (e.g., schools, healthcare, public safety, commerce) to address capacity building and quality improvement. Increased use of nationally established standards, such as those for public health department accreditation.*

*Increased number of qualified public health workers Implementation of culturally practice-based evidence programs and services Increased coordination of multisector partnerships to generate collect public health impact*

<https://www.grants.gov/web/grants/view-opportunity.html?opId=298670>

**Department of Health and Human Services - Centers for Disease Control – OSTLTS - Supporting Tribal Public Health Capacity in Coronavirus Preparedness and Response**

<b>Proposal Due Date:</b>	<b>May 31, 2020</b>
<b>Expected Number of Awards:</b>	<b>574</b>
<b>Estimated Total Program Funding:</b>	<b>\$40,000,000</b>
<b>Award Ceiling:</b>	<b>\$1,500,000</b>
<b>Award Floor:</b>	
<b>Funding Opportunity Number:</b>	<b>CDC-RFA-OT20-2004</b>

*Purpose: To support tribal public health emergency response to COVID-19, the Centers for Disease Control and Prevention (CDC) is announcing a new, non-competitive grant CDC-RFA-OT20-2004 Supporting Tribal Public Health Capacity in Coronavirus Preparedness and Response. CDC is awarding at least \$40,000,000 under this funding opportunity to Title I and Title V tribal nations to strengthen the tribal public health system to carry out surveillance, epidemiology, laboratory capacity, infection control, mitigation, communications, and other preparedness and response activities in response to COVID-19.*

*CDC is committed to helping ensure that tribal jurisdictions have adequate resources for an appropriate COVID-19 response. The continued support for and expansion of critical public health activities at the tribal level are essential to meet the needs in this quickly evolving response. Funds from this funding opportunity will be made available for a variety of activities including, but not limited to:*

*Emergency operations and coordination activities (e.g., establishing emergency operations centers, incident management systems, continuity of operations plans, etc.);*  
*Public health management and risk assessment of travelers and others with potential COVID-19 exposure; equipment, supplies, shipping activities, or others to strengthen jurisdictional recovery;*  
*Laboratory, surveillance, and epidemiologic (e.g., case identification) activities, data management activities, and others to strengthen bio surveillance;*  
*Risk communications activities, distribution and use of medical material, and others to strengthen information management;*  
*Activities to strengthen countermeasures and mitigation (e.g., storage and distribution systems, inventory management systems, points of dispensing (POD) alternative nodes, etc.;*  
*Surge staffing activities, infection control activities and others to strengthen surge management; and*  
*Other preparedness and response activities*

<https://www.grants.gov/web/grants/view-opportunity.html?opId=325942>

**Department of Health and Human Services - Health Resources and Services Administration - Telehealth Network Grant Program**

**Proposal Due Date:** May 1, 2020  
**Expected Number of Awards:** 29  
**Estimated Total Program Funding:** \$8,700,000  
**Award Ceiling:** \$300,000  
**Award Floor:**  
**Funding Opportunity Number:** HRSA-20-036

*Purpose: This notice announces the opportunity to apply for funding under the Telehealth Network Grant Program (TNGP). The funding opportunity is aimed towards promoting rural Tele-emergency services with an emphasis on tele-stroke, tele-behavioral health, and Tele-Emergency Medical Services (Tele-EMS). This will be achieved by enhancing telehealth networks to deliver 24-hour Emergency Department (ED) consultation services via telehealth to rural providers without emergency care specialists. Tele-emergency is defined as “an electronic, two-way, audio/visual communication service between a central emergency healthcare center (Tele-emergency hub) and a distant hospital emergency department (ED) (remote ED) designed to provide real-time emergency care consultation.”<sup>1</sup> These services may include assessment of patients upon admission to the ED, interpretation of patient symptoms and clinical tests or data, supervision of providers administering treatment or pharmaceuticals, or coordination of patient transfer from the local ED. The overarching goals for the Telehealth Network Grant Program are to: • Expand access to, coordinate, and improve the quality of health care services; • Improve and expand the training of health care providers; and • Expand and improve the quality of health information available to health care providers, and patients and their families, for decision-making. In addition, TNGP recipients will support a range of Tele-emergency service programs that will allow for the analysis of a significant volume of patient encounters. The goal is for each TNGP recipient, under this NOFO, to analyze the provision of Tele-emergency services under common metrics and protocols that will allow for a multi-site analysis of the effectiveness of those services. Each of the recipients will participate in a broad-scale analysis and evaluation of the program coordinated by the Federal Office of Rural Health Policy (FORHP) as well as individual award recipient analysis and evaluation.*

<https://www.grants.gov/web/grants/view-opportunity.html?opId=315882>

**Department of Health and Human Services - Substance Abuse and Mental Health Services Administration - Emergency Grants to Address Mental and Substance Use Disorders During COVID-19**

**Proposal Due Date:** April 10, 2020  
**Expected Number of Awards:** 560  
**Estimated Total Program Funding:** \$100,000,000  
**Award Ceiling:** \$2,000,000  
**Award Floor:**



**Funding Opportunity Number:****FG-20-006**

*Purpose: The Substance Abuse and Mental Health Services Administration (SAMHSA) is accepting applications for fiscal year (FY) 2020 Emergency Grants to Address Mental and Substance Use Disorders During COVID-19 (Short Title: Emergency COVID-19). SAMHSA recognizes there are currently 57.8 million Americans living with mental and/or substance use disorders (National Survey on Drug Use and Health, 2018). The current national crisis of COVID-19 will certainly contribute to growth in these numbers. Americans across the country will struggle with increases in depression, anxiety, trauma, and grief. There is also anticipated increase in substance misuse as lives are impacted for individuals and families. The purpose of this program is to provide crisis intervention services, mental and substance use disorder treatment, and other related recovery supports for children and adults impacted by the COVID-19 pandemic. Funding will be provided for states, territories, and tribes to develop comprehensive systems to address these needs. The purpose of this program is specifically to address the needs of individuals with serious mental illness, individuals with substance use disorders, and/or individuals with co-occurring serious mental illness and substance use disorders.*

<https://www.grants.gov/web/grants/view-opportunity.html?oppld=325993>

**Department of Homeland Security - FEMA - Fiscal Year (FY) 2019 Staffing for Adequate Fire and Emergency Response (SAFER)****Proposal Due Date:** April 10, 2020**Expected Number of Awards:** 300**Estimated Total Program Funding:** \$350,000,000**Award Ceiling:****Award Floor:****Funding Opportunity Number:** DHS-19-GPD-083-000-99

*Purpose: The Department of Homeland Security (DHS) Federal Emergency Management Agency's (FEMA) Grant Programs Directorate implements and administers the Staffing for Adequate Fire and Emergency Response (SAFER) Grants. SAFER grants provide financial assistance to help fire departments increase frontline firefighters. SAFER offers grants to support activities in two activities:*

- 1. Hiring of Firefighters*
- 2. Recruitment and Retention of Volunteer Firefighters*

*The authority for SAFER is derived from Section 34 of the Federal Fire Prevention and Control Act of 1974 (Pub. L. No. 93-498, as amended) (15 U.S.C. § 2229a).*

*The notice of funding opportunity document provides potential applicants with the details of the requirements, processing, and evaluation of an application for financial assistance for both of these activity areas.*

<https://www.grants.gov/web/grants/view-opportunity.html?oppld=326125>



## **Federal Communication Commission - Guidance on the COVID-19 Telehealth Program Application Process**

<b>Proposal Due Date:</b>	<b>September 20, 2020</b>
<b>Expected Number of Awards:</b>	
<b>Estimated Total Program Funding:</b>	<b>\$100,000,000</b>
<b>Award Ceiling:</b>	<b>\$1,000,000</b>
<b>Award Floor:</b>	
<b>Funding Opportunity Number:</b>	<b>DHS-19-GPD-083-000-99</b>

*Purpose: Interested health care providers must complete several steps to apply for funding through the COVID-19 Telehealth Program. This Public Notice is aimed at assisting applicants. There are three steps interested providers can take immediately to prepare to apply for the COVID-19 Telehealth Program: (1) obtain an eligibility determination from the Universal Service Administrative Company (USAC); (2) obtain an FCC Registration Number (FRN); and (3) register with System for Award Management. If an interested party does not already have these steps and accompanying components completed, the Bureau recommends that it gather the necessary information and begin to complete other necessary steps now, so it is prepared to submit applications for program funding as soon as applications can be accepted for filing. The Bureau will release a subsequent Public Notice announcing the application acceptance date immediately following the effective date of the COVID-19 Telehealth Program information collection requirements.*

<https://www.fcc.gov/document/guidance-covid-19-telehealth-program-application-process>

<https://www.federalregister.gov/documents/2020/04/09/2020-07587/promoting-telehealth-for-low-income-consumers-covid-19-telehealth-program>

## **Manufacturing/Technology Research Opportunities**

### **Department of Commerce - National Institute of Standards and Technology - NIST Manufacturing USA National Emergency Assistance Program**

**Proposal Due Date:** Applications for funding pursuant to this NOFO will be reviewed and considered on a rolling basis as they are received. Applications will be accepted until an amendment indicating 90 days to close this NOFO, subject to the publication of a superseding NOFO. Funding is subject to availability.

<b>Expected Number of Awards:</b>	
<b>Estimated Total Program Funding:</b>	
<b>Award Ceiling:</b>	<b>\$10,000,000</b>
<b>Award Floor:</b>	<b>\$250,000</b>
<b>Funding Opportunity Number:</b>	<b>2020-NIST-MFGUSA-NEAP-01</b>

*Purpose: Collectively, Manufacturing USA institutes have over 2,000 member institutions including small manufacturers, two-thirds of Fortune 50 U.S. manufacturers, and nearly every top ranked research and engineering university in the United States. Its network of research and development institutes that engage with these industry-led institutions positions it well to distribute high-impact funding into existing efforts in the manufacturing sector to both stimulate the US economy and to support efforts to respond to the COVID-19 pandemic and other public health crises.*

*Projects should focus on responding to the COVID-19 pandemic. Projects may include medical countermeasures; non-medical countermeasures; leveraging institute capabilities to strengthen state and community resilience; grants to companies and technical support to accelerate productions of critical materials, equipment, and supplies; creation of additional production facilities; technology roadmapping for pandemic response and recovery; reshoring the manufacture of critical conventional drugs and ensuring supply chain for critical materials related to pandemic response; or workforce development and training for a skilled advanced manufacturing workforce.*

<https://www.grants.gov/web/grants/view-opportunity.html?oppld=325811>

**Department of Defense – Department of the Army - Medical Technology Enterprise Consortium (MTEC) - National Emergency Telecritical Care Network (NETCCN) Project for Coronavirus**

<b>Enhanced White Paper Due Date:</b>	<b>April 30, 2020</b>
<b>Expected Number of Awards:</b>	
<b>Estimated Total Program Funding:</b>	<b>\$37,000,000</b>
<b>Award Ceiling:</b>	
<b>Award Floor:</b>	
<b>Solicitation Number:</b>	<b>MTEC-Presolicitation-NETCCN-</b>
<b>COVID-19</b>	

*Purpose: The Medical Technology Enterprise Consortium (MTEC) is excited to post this pre-announcement for a Request for Project Proposals (RPP) to rapidly develop and deploy the National Emergency Telecritical Care Network (NETCCN) - a cloud-based, low-resource, stand-alone health information management system for the creation and coordination of flexible and extendable “virtual critical care wards.” These high acuity, virtual wards would bring high-quality critical care capability to nearly every bedside, be it healthcare facility, field hospital, or gymnasium.*

*This program is specifically focused on preparation for COVID-19 related critical care capability shortages. Although the United States has more critical care beds per capita than other developed nations, emerging national and international experience with COVID-19-related critical illness suggests a high level of oncoming system stress on critical care resources and a likely potential for intensive care unit (ICU) beds and care teams to be overwhelmed.*

*Tele-critical care can be a powerful force-multiplier in the extension of limited critical care resources in both high-census urban centers and rural communities in which access to critical care – facilities, equipment and trained clinicians - is limited even under normal conditions. Many local and regional health systems have invested extensively in telemedicine capabilities, but many of these systems lack sufficient scalability, are limited both in interoperability with other telehealth systems and scope and reach of partner provider-networks and supported tele-clinical services.*

*Medical Technology Enterprise Consortium -- is the DoD's "OTA" consortia. OTA is Other Transaction Authority. OTAs are becoming popular b/c they by-pass the traditional constraints of the federal acquisition regulation (FAR) process. Under an OTA the government can move more quickly to award funding and can talk with the proposer about their grant application, requesting changes, suggesting they team with others, etc. This back-and-forth discussion is helpful for the government as it improves proposals to accomplish the government's goals and helpful for proposers as they can better understand how their work fits into the vision for a program. MTEC has awarded about \$70M so far in the last three years (including an award last year on volumetric muscle loss) to members of the consortia – which number about 300 at this point.*

*Here is information about how to join MTEC -- <https://www.mtec-sc.org/how-to-join-2/> You'll want to take a look at the agreement, especially the IP. The matching can often be fulfilled with in-kind uses of space, etc. In order to pursue most MTEC calls, you will have to have to join the consortia for a cost of \$500-\$1,000 or partner with an existing member to be a sub on their application.*

*MTEC anticipates releasing several COVID-19 RPPS. The first pre-announcement that was released lumped several initiatives together. Since we are issuing separate RPPS we decided to take the pre-announcement down from beta.sam.gov site because it contained outdated information.*

<https://www.mtec-sc.org/upcoming-solicitations/>

## **Department of Defense – Department of the Air Force – Commercial Solution Opening - CSO\_COVID\_19 Response**

**Proposal Due Date:**

**September 30, 2020**

**Expected Number of Awards:**

**Estimated Total Program Funding:**

**Award Ceiling:**

**Award Floor:**

**Funding Opportunity Number:**

**FA300220S0002**

***Purpose:** The Department of the Air Force (DAF) has been tasked to address mission needs in response to the national crisis caused by the COVID-19 pandemic. The Air Force Senior Acquisition Executive (SAE) established the Department of the Air Force Acquisition COVID-19 Task Force (DAF ACT) across the acquisition enterprise (i) to execute all requirements from the Office of the Under Secretary of Defense for Acquisition and Sustainment Joint Acquisition Task Force, (JATF) and (ii) to collect and consolidate*

*funding requests needed to recover programs from COVID-19 impacts. The DAF ACT contains four primary lines of effort (LOE's): (1) Relief for external assistance requirements; (2) Resilience for Defense Industrial Base Efforts; (3) Recovery for consolidating funding requests that minimize program impacts; and (4) Rapid for solicitation and execution of large-scale rapid small business contracts across all lines of effort.*

#### **MISSION FOCUS AREAS**

*I. Combating the Spread (predictive analytics, next hotspot, threat to current activities, decision support, etc.)*

*II. Welfare of Citizens (effects to transportation, movement of people and goods, education and development, physical training, regular HR functions, job transition, etc.)*

*III. Readiness (continuing operations through the outbreak, coordinating with allies and partners, continuing long term projects, etc.)*

*IV. Logistics (security and protection, supply chain protection and assessment, etc.)*

*V. Industrial Base Impacts (impacts on small businesses, payments, contracts, large system programs, protection and expansion of critical assets, etc.)*

*VI. Medical (telehealth, medical capacity and sustainment, medical supplies and equipment, etc.)*

*VII. Other - Any solution/proposal that is not covered by the above topic areas but support the national response to the COVID-19 pandemic*

**Contact:** Jessica.Steinhoff, Maj, USAF [jess.steinhoff@afwerx.af.mil](mailto:jess.steinhoff@afwerx.af.mil)

<https://beta.sam.gov/opp/f48d23af514f494f819f0c33e9f40e17/view>

### **Department of Health and Human Services - Office of the National Coordinator for Health Information Technology (ONC) - Tools and Resources for the Health IT and Clinical Community**

*Purpose: To support HHS's ongoing response efforts to the outbreak of Coronavirus Disease 2019 (COVID-19), ONC has partnered with the Centers for Disease Control and Prevention (CDC) to share various resources for reporting and tracking COVID-19, as well as general clinical guidance to the health IT community and healthcare providers. Health IT now plays a crucial role in the collecting and reporting of COVID-19 data. Additionally, electronic health information exchange can facilitate effective strategies to combat COVID-19, including:*

*Surveillance*

*Public health reporting*

*Laboratory testing*

*Clinical data collection*

*Case investigation and management*

*Reporting outcomes*

*Workforce Safety and Health (please visit <https://www.cdc.gov/niosh/index.htm>)*

The link contains resources created by CDC, ONC, and other partners, which the health IT community and healthcare providers can reference as HHS works to respond to this emerging disease. Please note that edits/additions will be made to the resources below when new information becomes available.

<https://www.healthit.gov/coronavirus>

## **Medical Research Opportunities**

### **Department of Defense – Department of the Air Force – Commercial Solution Opening - CSO\_COVID\_19 Response**

**Proposal Due Date:** September 30, 2020

**Expected Number of Awards:**

**Estimated Total Program Funding:**

**Award Ceiling:**

**Award Floor:**

**Funding Opportunity Number:** FA300220S0002

***Purpose:** The Department of the Air Force (DAF) has been tasked to address mission needs in response to the national crisis caused by the COVID-19 pandemic. The Air Force Senior Acquisition Executive (SAE) established the Department of the Air Force Acquisition COVID-19 Task Force (DAF ACT) across the acquisition enterprise (i) to execute all requirements from the Office of the Under Secretary of Defense for Acquisition and Sustainment Joint Acquisition Task Force, (JATF) and (ii) to collect and consolidate funding requests needed to recover programs from COVID-19 impacts. The DAF ACT contains four primary lines of effort (LOE's): (1) Relief for external assistance requirements; (2) Resilience for Defense Industrial Base Efforts; (3) Recovery for consolidating funding requests that minimize program impacts; and (4) Rapid for solicitation and execution of large-scale rapid small business contracts across all lines of effort.*

#### **MISSION FOCUS AREAS**

*I. Combating the Spread (predictive analytics, next hotspot, threat to current activities, decision support, etc.)*

*II. Welfare of Citizens (effects to transportation, movement of people and goods, education and development, physical training, regular HR functions, job transition, etc.)*

*III. Readiness (continuing operations through the outbreak, coordinating with allies and partners, continuing long term projects, etc.)*

*IV. Logistics (security and protection, supply chain protection and assessment, etc.)*

*V. Industrial Base Impacts (impacts on small businesses, payments, contracts, large system programs, protection and expansion of critical assets, etc.)*

*VI. Medical (telehealth, medical capacity and sustainment, medical supplies and equipment, etc.)*

*VII. Other - Any solution/proposal that is not covered by the above topic areas but support the national response to the COVID-19 pandemic*

**Contact:** Jessica.Steinhoff, Maj, USAF [jess.steinhoff@afwerx.af.mil](mailto:jess.steinhoff@afwerx.af.mil)

<https://beta.sam.gov/opp/f48d23af514f494f819f0c33e9f40e17/view>

## **Department of Defense – Newton Award for Transformative Ideas during the COVID-19 Pandemic**

<b>Response Date:</b>	<b>May 15, 2020</b>
<b>Expected Number of Awards:</b>	<b>10</b>
<b>Estimated Total Program Funding:</b>	<b>\$500,000</b>
<b>Award Ceiling:</b>	<b>\$100,000</b>
<b>Award Floor:</b>	<b>\$10,000</b>
<b>Solicitation Number:</b>	<b>BRO-20-NEWTON</b>

***Purpose:** Background: From 1665 to 1666, the Great Plague of London swept across England, likely taking the lives of over 100,000 people (United Kingdom Public Archives, 2020). Though the germ theory of disease would not be formulated until the 1860s, the English public engaged in “social distancing” behaviors to avoid illness (Washington Post, 2020), leading to the closure of universities. Among the displaced was a young Isaac Newton, still a student at Trinity College in Cambridge. During the ensuing year of isolated study and reflection, Newton developed the basis for calculus, as well as foundational theories in gravitation, motion, and optics.*

*Separated from the Great Plague by 350 years, the COVID-19 pandemic has led to similar health responses among the general public and scientific community, forcing the closure of laboratories and universities throughout the world and slowing scientific progress across theoretical and empirical domains. To help stimulate scientific thought and encourage efforts and advancements in the spirit of Sir Isaac, the Basic Research Office in the U.S. Department of Defense (DoD) announces the Newton Award for Transformative Ideas during the COVID-19 Pandemic.*

***Program Objective:** This award will be presented to a single investigator or team of up to two investigators that develops a “transformative idea” to resolve challenges, advance frontiers, and set new paradigms in areas of immense potential benefit to DoD and the nation at large. Proposals should aim to produce novel conceptual frameworks or theory-based approaches that present disruptive ways of thinking about fundamental scientific problems that have evaded resolution, propose new, paradigm-shifting scientific directions, and/or address fundamental and important questions that are argued to be undervalued by the scientific community. Approaches can include analytical reasoning, calculations, simulations, and thought experiments. While data collection and production are therefore allowed, all supporting data should be generated without the use of laboratory-based experimentation or instrumentation.*

*Given the novelty of and circumstances surrounding this one-time Funding Opportunity Announcement (FOA), the objective of this program is to generate proposals that are equally novel and pioneering.*



Therefore, this FOA should be viewed as an opportunity to propose work outside the bounds of traditional proposals.

\  
*Expectations of Award Recipients: Newton Award recipients will produce novel conceptual frameworks or theoretical approaches to addressing outstanding or emerging challenges facing the scientific community. The resulting frameworks and approaches should include clear predictions that can be tested by the scientific community in the years following the return to the laboratory environment. Findings must be submitted as pre-publication material in open archives and disseminated through open publication in a journal. Award winners will brief the Office of the Undersecretary of Defense for Research and Engineering (OUSD(R&E)) leadership at the end of the award period of performance, and may be asked to design and chair a Future Directions Workshop on the topic of their findings. In addition, OUSD(R&E) will support winners with successful projects in finding pathways to continue the funding of their transformative ideas.*

<https://www.grants.gov/web/grants/view-opportunity.html?opId=326034>

**Department of Defense – Department of the Army - Medical CBRN Defense Consortium (MCDC) - Medical CBRN Defense Consortium (MCDC) Other Transaction Agreement (OTA) Request for Information (RFI) - CoV Pandemic Response**

**White Paper Due Date:** Offerors are strongly encouraged to submit within 48 hours of the issue date of this RFI (March 19, 2020). However, this is an open RFI, and submissions will be accepted through the end date of May 31, 2020

***Purpose:** The purpose of this special notice is to obtain information via White Papers from both MCDC members and other interested industry/academia partners in response to the novel Coronavirus (2019-nCoV) pandemic in the United States (U.S.). The Government is requesting White Papers with a focus on the following areas:*

- *Diagnosics/Monitoring: Medical diagnostic devices, with specific emphasis on Point-of-Care diagnostics (e.g. CLIA waived), under development and capable of diagnosing 2019- SARS-CoV-2, and achieving Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA) within the next one to four (1-4) months.*
- *Surveillance: Surveillance methods and associated devices for 2019-SARS-CoV-2 screening. Any technology that can enhance the understanding of disease progression in COVID-19 infected patients is also of interest, including physiologic monitoring and other vital signs indicators, portable technology that enhances patient care in non-hospital settings, and technology that improves sample collection.*

*Note: Offerors can consider pursuing Assay and/or Device development efforts that could be used for health surveillance, medical diagnostics, or potentially both. Medical diagnostics efforts need to ensure that they meet required regulatory pathways.*



- *Information systems and technology the Government can use in a handheld Point-of-Care device to collect, screen, collate, report, and monitor disease infection and pandemic spread on a micro and macro level.*
- *Therapeutics: Drugs and/or drug/device combinations, or platforms currently under development demonstrating efficacy in post-exposure, pre- and post-symptomatic studies for any CoV strain, and capable of achieving EUA from the FDA within the next three (3) months for this ongoing SARS-CoV-2 pandemic. Antibody technologies, accelerating the discovery, development, manufacturing, and prediction of success for these technologies, can also be considered.*
- *Prophylactics: Drugs or vaccines currently under development demonstrating pre-exposure in vivo efficacy or in vitro activity against any or all strains of CoV. Antibody technology, accelerating the discovery, development, manufacturing and prediction of success for these technologies can be considered.*
- *Clinical Trials: Opportunities to expeditiously conduct clinical trials for any technology that will require evaluation for FDA approval, will be considered.*

*This request is Market Research to determine the capability of the industrial base to respond to the 2019-nCoV pandemic. At this time, funding has not been identified for any prototype projects under this request.*

*Entities are encouraged to provide innovative products and technologies that in the short term (1-6 months), can be rapidly deployed to combat the current pandemic. Long-term solutions (6 months and beyond) are not requested at this time.*

*It is expected the proposed solutions will be submitted to, and receive FDA EUA.*

*By submission of a White Paper in response to this request, the offeror agrees that even if marked as proprietary information in the White Paper, the Government has full authority to distribute the White Paper to any other Government agency requesting it. The proprietary information will be handled accordingly. White Papers will not be returned to the member and may be retained indefinitely by the Government. The White Papers will not be subjected to a source selection review process, therefore, no White Paper Feedback will be provided.*

*MCDC Membership: The OTA Consortium model allows for increased, streamlined collaboration between the Government and Consortium membership. The OTA Consortium model is a unique acquisition tool that allows for more open communication and emphasizes engaging a diversified range of membership - from academia to industry suppliers. The MCDC Consortium model operates via a single set of terms and conditions through the single-point contracting agent for the Consortium, or Consortium Management Firm (CMF). As a result, the OTA process decreases acquisition time and cost, enabling rapid technology and prototype solutions. Membership in the MCDC Consortium allows for networking with stakeholders including Government, Industry, and Academia.*

*Interested parties can be directed to <https://www.medcbrn.org/how-to-join/> to obtain information on membership. Companies that are part of the Academia, US Defense Industrial Base, as well as new and*

emerging non-traditional defense contractors, are encouraged to join the MCDC and participate in Federally-funded R&D projects. Any questions should be addressed to the CMF, Advanced Technology International (ATI), at [MCDC@ati.org](mailto:MCDC@ati.org)

**Contact:** Alexis Hurr, [alexis.hurr@ati.org](mailto:alexis.hurr@ati.org), P. 843-760-3374 Dr. Mike Stebbins, [mike.stebbins@ati.org](mailto:mike.stebbins@ati.org), P. 843-760-4094 MCDC Contracts Box, [contracts.mcdc@ati.org](mailto:contracts.mcdc@ati.org)

<https://www.medcbrn.org/solicitations/>

**Department of Defense – Department of the Army - Medical Technology Enterprise Consortium (MTEC) - National Emergency Telecritical Care Network (NETCCN) Project for Coronavirus**

<b>Enhanced White Paper Due Date:</b>	<b>April 30, 2020</b>
<b>Expected Number of Awards:</b>	
<b>Estimated Total Program Funding:</b>	<b>\$37,000,000</b>
<b>Award Ceiling:</b>	
<b>Award Floor:</b>	
<b>Solicitation Number:</b>	<b>MTEC-Presolicitation-NETCCN-</b>
<b>COVID-19</b>	

*Purpose: The Medical Technology Enterprise Consortium (MTEC) is excited to post this pre-announcement for a Request for Project Proposals (RPP) to rapidly develop and deploy the National Emergency Telecritical Care Network (NETCCN) - a cloud-based, low-resource, stand-alone health information management system for the creation and coordination of flexible and extendable “virtual critical care wards.” These high acuity, virtual wards would bring high-quality critical care capability to nearly every bedside, be it healthcare facility, field hospital, or gymnasium.*

*This program is specifically focused on preparation for COVID-19 related critical care capability shortages. Although the United States has more critical care beds per capita than other developed nations, emerging national and international experience with COVID-19-related critical illness suggests a high level of oncoming system stress on critical care resources and a likely potential for intensive care unit (ICU) beds and care teams to be overwhelmed.*

*Tele-critical care can be a powerful force-multiplier in the extension of limited critical care resources in both high-census urban centers and rural communities in which access to critical care – facilities, equipment and trained clinicians - is limited even under normal conditions. Many local and regional health systems have invested extensively in telemedicine capabilities, but many of these systems lack sufficient scalability, are limited both in interoperability with other telehealth systems and scope and reach of partner provider-networks and supported tele-clinical services.*

<https://beta.sam.gov/opp/245ccb8f39a4423ab26468225e5e788c/view>

## Department of Defense - Department of the Army - USAMRDC New Products and Ideas

### Proposal Due Date:

See link

*Purpose: The United States Army Medical Research and Development Command (USAMRDC) utilizes the New Products and Ideas (NPI) system as a mechanism to have visibility and evaluate new products and ideas, currently configured or in development, that support our mission. The NPI provides a means for our subject matter experts to assess these products and ideas, evaluate their applicability to USAMRDC's mission, and provide feedback to the submitter. It provides the vendor an opportunity to showcase their product or idea without needing to travel to Fort Detrick and without giving anyone an unfair competitive advantage.*

*Submission to the NPI is not a substitute where other vehicles are more appropriate, such as responding to Requests for Proposals (RFPs), the Broad Agency Announcement (BAA) or Program Announcements (PAs), nor does it take the place of a pre-proposal that may be required by a BAA or PA.*

*Who should apply to NPI:*

<https://www.usamriid.army.mil/docs/USAMRDCCOVID19DiagntosisInformationPaper.pdf>

<https://mrdc-npi.amedd.army.mil/>

## Department of Defense – Department of the Army - Defense Biological Product Assurance Office's (DBPAO) - Development of Lateral Flow Immunoassays (LFI) for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

**Response Date:**

**April 10, 2020**

**Expected Number of Awards:**

**Estimated Total Program Funding:**

**Award Ceiling:**

**Award Floor:**

**Funding Opportunity Number:**

**W911QY-20-S-0006**

***Purpose:** Defense Biological Product Assurance Office's (DBPAO) mission is to employ best practices in providing the Department of Defense and its partners with a comprehensive collection of biological products that are: thoroughly characterized, of the highest quality, adaptable and traceable from source to application.*

*The DBPAO is seeking interested parties to develop Lateral Flow Immunoassays (LFIs) for screening for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). No government funding is provided for developmental efforts of this LFI. The DBPAO seeks the development of an easy to use, hand held LFI for detecting SARS-CoV-2 virus in specimens from infected persons or persons suspected of viral exposure as a screening tool. The LFIs will be used with nasopharyngeal swab specimens, just as existing Polymerase Chain Reaction (PCR) tests are used. The desired LFIs are expected to be*

conventional assays where the results are manually read by eye. The DBPAO has no specified assay format or specific reagents to be used.

The DBPAO requires a lot of 5000 LFIs devices for testing and evaluation to be delivered to a contracted third party by 24 April 2020. The DBPAO requires potential submitters to provide appropriate clinical buffer and nasal swabs as part of the kit. For third party testing, the submitters also are required to provide for the other reagents and antigens or positive controls used for their internal testing.

**Contact:** Leo J. Fratis [leo.j.fratis.civ@mail.mil](mailto:leo.j.fratis.civ@mail.mil) Phone Number 2405861523

<https://beta.sam.gov/opp/8e81ad9648ef485ebf9c3f62e5c85fa8/view>

**Department of Defense - Department of the Army – USAMRAA - CDMRP PRMRP Technology/Therapeutic Development Award for Emerging Viral Diseases and Respiratory Health \*\***

<b>Pre-Application Submission Deadline:</b>	<b>May 28, 2020</b>
<b>Proposal Due Date:</b>	<b>June 12, 2020</b>
<b>Expected Number of Awards:</b>	<b>4</b>
<b>Estimated Total Program Funding:</b>	<b>\$25,000,000</b>
<b>Award Ceiling:</b>	
<b>Award Floor:</b>	
<b>Funding Opportunity Number:</b>	<b>W81XWH-20-PRMRP-TTDA-COV</b>

*Purpose: The PRMRP Technology/Therapeutic Development Award is a product-driven award mechanism intended to provide support for the translation of promising preclinical findings into products for clinical applications in one or more Focus Areas published in this funding opportunity for the FY20 PRMRP Topic Areas of Emerging Viral Diseases and/or Respiratory Health. Products in development should be responsive to the healthcare needs of military Service members, Veterans, and/or beneficiaries.*

*The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product. (A "Knowledge Product" is a non-materiel product that addresses an identified need in a Topic Area, is based on current evidence and research, aims to transition into medical practice, training, tools, or to support materiel solutions [systems to develop, acquire, provide, and sustain medical solutions and capabilities], and educates or impacts behavior throughout the continuum of care, including primary prevention of negative outcomes.) The Principal Investigator (PI) must provide a transition plan (including potential funding and resources, see Attachment 8) showing how the product will progress to the next level of development (e.g., clinical trials, delivery to the military or civilian market) after the completion of the PRMRP award. PIs are encouraged to develop relationships with industry and/or other funding agencies to facilitate moving the product into the next phase of development.*

*Proof of concept demonstrating the potential utility of the proposed product, or a prototype/preliminary version of the proposed product, should already be established. Applications must include relevant data that support the rationale for the proposed study. These data may be unpublished and/or from the published literature.*

<https://www.grants.gov/web/grants/view-opportunity.html?oppld=326175>

**Department of Defense - Department of the Army – USAMRAA - CDMRP PRMRP Investigator-Initiated Research Award for Emerging Viral Diseases and Respiratory Health\*\***

<b>Pre-Application Submission Deadline:</b>	<b>May 28, 2020</b>
<b>Proposal Due Date:</b>	<b>June 12, 2020</b>
<b>Expected Number of Awards:</b>	<b>4</b>
<b>Estimated Total Program Funding:</b>	<b>\$12,000,000</b>
<b>Award Ceiling:</b>	
<b>Award Floor:</b>	
<b>Funding Opportunity Number:</b>	<b>W81XWH-20-PRMRP-IIRA-COV</b>

*Purpose: The PRMRP Investigator-Initiated Research Award is intended to support studies that will make an important contribution toward research and/or patient care in one or more Focus Areas published in this Funding Opportunity for the FY20 PRMRP Topic Areas of Emerging Viral Diseases and/or Respiratory Health.*

*The rationale for a research idea may be derived from a laboratory discovery, population-based studies, a clinician’s first-hand knowledge of patients, or anecdotal data. Applications must include relevant data that support the rationale for the proposed study. These data may be unpublished or from the published literature.*

*Impact: The Investigator-Initiated Research Award is designed to support research with the potential to yield highly impactful data that could lead to critical discoveries or major advancements. The application must clearly demonstrate the project’s potential short-term and long-term outcome(s)/product(s) (knowledge and/or materiel) and how they will impact a critical problem or question in the field of research and/or patient care in one or more Focus Areas published in this funding opportunity for the FY20 PRMRP Topic Area(s) of Emerging Viral Diseases and/or Respiratory Health.*

*Research projects may focus on any phase of research from basic laboratory research through translational research, including preclinical studies in animal models and human subjects, as well as correlative studies associated with an existing clinical trial. Research involving human subjects and human anatomical substances is permitted; however, this award may not be used to conduct clinical trials. For more information on how to distinguish clinical research from clinical trials, see the Human Subject Resource Document at <https://ebrap.org/eBRAP/public/Program.htm>.*

<https://www.grants.gov/web/grants/view-opportunity.html?oppld=326174>

**Department of Defense - Department of the Army – USAMRAA - CDMRP PRMRP Clinical Trial Award for Emerging Viral Diseases and Respiratory Health\*\***

**Pre-Application Submission Deadline:** May 28, 2020

**Proposal Due Date:** June 22, 2020

**Expected Number of Awards:** 5

**Estimated Total Program Funding:** \$30,000,000

**Award Ceiling:**

**Award Floor:**

**Funding Opportunity Number:** W81XWH-20-PRMRP-CTA-COV

*Purpose: The PRMRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact in one or more of the Focus Areas published in this funding opportunity for the FY20 PRMRP Congressionally specified Topic Areas of Emerging Viral Diseases and Respiratory Health. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first in human, Phase 0), to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations.*

*Funding from this award mechanism must support a clinical trial and cannot be used for animal studies. A clinical trial is defined as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. This outcome represents a direct effect on the subject of that intervention or interaction. The term "human subjects" is used in this Program Announcement to refer to individuals who will be recruited for or who will participate in the proposed clinical trial. For more information, a Human Subject Resource Document is provided at <https://ebrap.org/eBRAP/public/Program.htm>. Applicants seeking funding for a preclinical research project should consider one of the other FY20 PRMRP Program Announcements being offered.*

<https://www.grants.gov/web/grants/view-opportunity.html?opId=326173>

**Department of Health and Human Services - National Institutes of Health - National Institute on Minority Health and Health Disparities (NIMHD) - Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities\*\***

**Proposal Due Date:** May 1, 2021

**Funding Opportunity Number:** NOT-MD-20-019

*Purpose: The National Institute on Minority Health and Health Disparities (NIMHD) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the impact of the novel Coronavirus (SARS-CoV-2) pandemic causing COVID-19 disease outbreaks and the resulting disruptions*



on individual and social wellbeing, health services use, and health outcomes for NIH-designated health disparity populations.

<https://grants.nih.gov/grants/guide/notice-files/NOT-MD-20-019.html>

**Department of Health and Human Services - National Institutes of Health - National Institute of Mental Health (NIMH) - Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus\*\***

**Proposal Due Date:**

**April 16, 2021**

**Funding Opportunity Number:**

**NOT-MH-20-047**

*Purpose: NIMH is issuing this Notice of Special Interest (NOSI) to highlight interest in research to strengthen the mental health response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and to future public health emergencies, including pandemics. NIMH is especially interested in research to provide an evidence base for how a disrupted workforce may adequately respond/adapt to and maintain services or provide additional care for new or increasing mental health needs, as well as to learn about the effects of the virus and public health measures to prevent spread of COVID-19 that may have an impact on mental health. Research addressing the intersection of COVID-19, mental health, and HIV treatment and prevention are also of interest to NIMH.*

<https://grants.nih.gov/grants/guide/notice-files/NOT-MH-20-047.html>

**Department of Health and Human Services - National Institutes of Health -National Cancer Institute (NCI) - Notice of Special Interest (NOSI): National Cancer Institute Announcement regarding Availability of Competitive Revision SBIR/STTR Supplements on Coronavirus Disease 2019 (COVID-19) \*\***

**Proposal Due Date:**

**June 26, 2020**

**Funding Opportunity Number:**

**NOT-CA-20-043**

*Purpose: The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs at the National Cancer Institute (NCI) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for the development of prophylactic, therapeutic and diagnostic for Coronavirus Disease 2019 (COVID-19). To accelerate the development of promising technologies, the NCI encourages applications from small businesses with NCI-funded active SBIR/STTR awards for technologies that have a strong potential to be adapted/repurposed for use as a prophylactic, therapeutic or diagnostic tool for SARS-CoV-2 (COVID-19).*

<https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-043.html>



**Department of Health and Human Services - National Institutes of Health - National Institute on Deafness and Other Communication Disorders (NIDCD) - Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) \*\***

**Proposal Due Date:** June 2, 2020  
**Funding Opportunity Number:** NOT-DC-20-004

*Purpose: In order to rapidly improve our understanding of the infection of SARS-CoV-2 and of COVID-19, NIDCD is encouraging the submission of applications for supplements to active NIDCD grants to address the pathology, prevention, diagnosis, sequelae, or treatment of COVID-19 directly related to NIDCD's mission areas.*

*Applications are expected to focus on immediate needs to help address the COVID-19 pandemic in a timely manner. Applications that are not responsive will be withdrawn without review.*

<https://grants.nih.gov/grants/guide/notice-files/NOT-DC-20-004.html>

**Department of Health and Human Services - National Institutes of Health - National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) - Notice of Special Interest (NOSI): Availability of Urgent Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIDDK\*\***

**Proposal Due Date:** June 2, 2020  
**Funding Opportunity Number:** NOT-DK-20-018

*Purpose: NIDDK is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19). NIDDK is particularly interested in projects focusing on the direct action of the virus on kidney, gastrointestinal tract function, and the endocrine/metabolic system, and the collection of biosamples that will inform the understanding of renal, gastrointestinal, and endocrine/metabolic sequelae of viral infection. Pilot clinical studies (observational and interventional) that support the understanding or treatment of COVID-19-related diseases within the mission of the NIDDK are also of interest. NIDDK will only consider applications that propose projects that may lead to rapid translation and impact in the COVID-19 emergency to be responsive to this NOSI.*

<https://grants.nih.gov/grants/guide/notice-files/NOT-DK-20-018.html>

**Department of Health and Human Services - National Institutes of Health - Competing Revisions to Existing NIH Grants and Cooperative Agreements (Clinical Trial Optional)**

**Proposal Due Date:** See Link  
**Funding Opportunity Number:** PA-20-163

*Purpose: The National Institutes of Health (NIH) hereby notifies NIH award recipients that funds may be available for revision applications to support the expansion of existing projects and/or programs within the awarding IC identified in the competitive revision NOSI. Applications for Revisions will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s), in accordance with NIH peer review policy and procedures, using the stated review criteria.*

*Only applications submitted in response to a NOSI published by an NIH Institute or Center will be allowed to apply to this FOA.*

<https://grants.nih.gov/grants/guide/pa-files/PA-20-163.html>

**Department of Health and Human Services - National Institutes of Health - National Human Genome Research Institute - Notice of NHGRI's Participation in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)"**

**Proposal Due Date:**

**See link**

**Funding Opportunity Number:**

**NOT-AI-20-034**

*Purpose: The purpose of this Notice is to inform applicants that the National Human Genome Research Institute (NHGRI) will participate, effective immediately, in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)".*

<https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html>

**Department of Health and Human Services - National Institutes of Health - National Institute of Allergy and Infectious Diseases (NIAID) - Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)**

**Proposal Due Date:**

**March 25, 2021**

**Funding Opportunity Number:**

**NOT-AI-20-031**

*Purpose: NIAID is issuing this Notice of Special Interest (NOSI) to highlight the need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19. NIAID is therefore encouraging applications to address research objectives described below.*

<https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-031.html>

**Department of Health and Human Services - National Institutes of Health - National Institute of Allergy and Infectious Diseases (NIAID) - Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)**

**Proposal Due Date:**

**March 25, 2021**

**Funding Opportunity Number:**

**NOT-AI-20-034**

*Purpose: Coronaviruses are a diverse family of viruses that cause a range of disease in humans and animals, and there are currently no approved coronavirus vaccines or therapeutics. In January 2020, a novel coronavirus was identified as the causative agent of a now global pandemic of viral pneumonia. Current information regarding confirmed cases is changing daily and can be found on the Centers for Disease Control and Prevention website (<https://www.cdc.gov/coronavirus/index.html>) and through other sources. Transmission characteristics and the associated morbidity and mortality are not completely understood, but there is clear evidence of human-to-human transmission. Many other aspects of viral pathogenesis, natural history, and host range are poorly understood. Given this, there is an urgent public health need to better understand SARS-CoV-2/COVID-19, particularly to improve understanding of fundamental virology, immunology, and the development of animal models and medical countermeasures.*

*Research Objectives*

*In order to rapidly improve our understanding and available control measures for SARS-CoV-2 and COVID-19, NIAID is encouraging the submission of applications for Competitive Revisions to active grants to address the following research areas of interest:*

- Studies to identify optimal in vitro culture requirements and conditions;*
- Development of reagents and assays for virus characterization;*
- Studies to understand critical aspects of viral infection, replication, pathogenesis, and transmission;*
- Studies to identify viral epitopes critical for binding neutralization;*
- Studies to examine virus stability and persistence;*
- Production of molecular clones of SARS-CoV-2, reporter viruses and recombinant viral proteins;*
- Development of animal models of SARS-CoV-2 infection suitable for screening vaccine and therapeutic candidates and/or pathogenesis studies;*
- Studies on the evolution and emergence of SARS-CoV-2 viruses including the identification of factors that affect viral host-range and virulence;*
- Virologic and serologic surveillance studies of the distribution and natural history of SARS-CoV-2 viruses in animal populations and in humans at the human/animal interface with particular emphasis on host reservoirs and understanding cross-species transmission events;*
- Development of sensitive, specific, and rapid clinical diagnostic tests for SARS-CoV-2;*
- Development of SARS-CoV-2 therapeutic candidates; broad-spectrum therapeutics against multiple coronavirus strains; examination of SARS-CoV-2 antiviral activity of existing or candidate therapeutics initially developed for other indications;*

*Identification and evaluation of the innate, cellular and humoral immune responses to SARS-CoV-2 infection and/or candidate vaccines, including, but not limited to: cross-reactive antibodies from individuals exposed to SARS-CoV-2 and other coronaviruses; viral epitopes critical for antibody binding and neutralization; immune-mediated pathology or host factors that might predispose to severe infection; and*

*Development of SARS-CoV-2 vaccine candidates that include emerging antigen design strategies, novel platforms or delivery approaches, adjuvants, or assessing cross-neutralization potential of SARS-CoV vaccine candidates.*

*Application and Submission Information*

<https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-034.html>

**Department of Health and Human Services - National Institutes of Health - National Center for Advancing Translational Sciences - Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus\*\***

**Proposal Due Date:**

**January 26, 2022**

**Funding Opportunity Number:**

**NOT-TR-20-017**

*Purpose: NCATS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the COVID-19. NCATS is especially interested in research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.*

*NCATS will accept the submission of applications for Competitive Revisions to active grants to address only the following research areas of interest:*

*Incorporation of new and emerging data related to SARS-CoV-2 into ongoing research efforts to develop microphysiological systems/tissue chips models for COVID-19*

*Use of microphysiological systems/tissue chips or evaluating, repurposing or modification of diagnostic tools to enable rapid detection of COVID-19 infection*

*Use of microphysiological systems/tissue chips for the rapid development and assessment of potential therapeutic agents for COVID-19*

*Applications that are not responsive to the above research areas of interest will be withdrawn without review.*

*A multi-organ on chip approach is strongly encouraged though not required. Please document access to a BSL-3 facility or include scientific justification for use of alternative facilities, for example using an engineered a COVID-19 pseudovirus that expresses the key surface Spike protein, which mediates its entry into cells.*

<https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-017.html>

**Department of Health and Human Services - National Institutes of Health - National Center for Advancing Translational Sciences - Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus \*\***

**Proposal Due Date:**

**January 26, 2022**

**Funding Opportunity Number:**

**NOT-TR-20-016**

*Purpose: NCATS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the COVID-19. NCATS is especially interested in research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.*

*A multi-organ on chip approach is strongly encouraged though not required. Please document access to a BSL-3 facility or include scientific justification for use of alternative facilities, for example using an engineered a COVID-19 pseudovirus that expresses the key surface Spike protein, which mediates its entry into cells.*

*Coronaviruses are a diverse family of viruses that cause a range of disease in humans and animals, and there are currently no approved coronavirus vaccines or therapeutics. A novel coronavirus, 2019-nCoV, also known as COVID-19 or SARS-CoV-2, was identified as the causative agent of an outbreak of viral pneumonia centered around Wuhan, China. Current information regarding confirmed cases is changing daily and can be found on the Centers for Disease Control and Prevention website (<https://www.cdc.gov/coronavirus/index.html>) and through other sources. Transmission characteristics and the associated morbidity and mortality are not completely understood, but there is clear evidence of human-to-human transmission. The virus appears to bind to the angiotensin-converting enzyme 2 (ACE2) receptor in humans, which is highly expressed in the lung alveolar epithelial cells and enterocytes of the small intestine, kidney, vascular endothelium, arterial smooth muscles and heart. Patients diagnosed with this illness have reported symptoms such as fever, cough, shortness of breath, fatigue, myalgias, headache, sore throat, abdominal pain, and diarrhea. Patients admitted to the hospital generally have pneumonia and abnormal chest imaging, and complications include acute respiratory failure, acute respiratory distress syndrome (ARDS), and acute myocardial injury. ARDS appears to be a significant predictor of mortality. Many other aspects of the disease are still poorly understood. Given this, there is an urgent public health need to better understand the COVID-19 to facilitate the identification of diagnostics, vaccines and therapeutics.*

<https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-016.html>

**Department of Health and Human Services - National Institutes of Health - National Center for Advancing Translational Sciences - Notice of Special Interest (NOSI): Clinical**

**and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need**

**Proposal Due Date:**

**May 4, 2020**

**Funding Opportunity Number:**

**NOT-TR-20-011**

*Purpose: National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel Coronavirus (COVID-19). NCATS is particularly interested in projects focusing on the use of informatics solutions to diagnose cases and the use of CTSA-supported core resources (e.g., advanced scientific instruments, highly-specialized facilities, and regulatory expertise) to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines. NCATS is soliciting applications for Administrative Supplements to UL1, U01, and R21 awards (through PA-18-591), Collaborative Innovation Awards to U01 and R21 awards (through PAR-19-099 and PAR-19-100, respectively), and Competitive Revisions for UL1 awards for each of the non-administrative supplement awards (through PAR-19-337).*

<https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-011.html>

**Department of Health and Human Services - National Center for Advancing Translational Sciences - Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19)**

**Proposal Due Date:**

**See below**

**Funding Opportunity Number:**

**NOT-TR-20-012**

*Purpose: National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel coronavirus (SARS-CoV-2) and the disease it causes, i.e., "coronavirus disease 2019" (COVID-19). NCATS is particularly interested in projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial.*

*The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair. Examples include the following:*

*Testing a publicly posted therapeutic candidate for use to treat COVID-19. Examples include clinical candidate therapeutics in documents publicly posted by the World Health Organization (types/classes of candidate therapeutics) and (candidates for clinical evaluation).*

*Testing a candidate therapy to treat COVID-19 that was already identified with a publicly available computational approach.*

*Testing of existing therapeutic candidates that work on mechanistic targets shared among other viruses that may be relevant to SARS-CoV-2.*

*NCATS is soliciting applications to PAR-17-465, PAR-18-462, and PAR-18-332.*



*PAR-17-465: Bench Testing Therapeutic/Indication Pairing Strategies (UG3/UH3)  
Applicable Receipt Date: June 26, 2020*

*PA-18-462: Clinical Trial Planning: Therapeutic/Indication Pairing Strategies (U34) (Clinical Trial Not Allowed)  
Applicable Receipt Date: June 16, 2020 and October 16, 2020*

*PAR-18-332: Clinic Testing Therapeutic/Indications Pairing Strategies (U01 Clinical Trial Required)  
Applicable Receipt Date: June 5, 2020 and October 5, 2020*

<https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-012.html>

**Department of Health and Human Services - National Institutes of Health - National Institute of General Medical Sciences - Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2**

**Proposal Due Date:**

**February 06, 2021**

**Funding Opportunity Number:**

**NOT-GM-20-025**

*Purpose: Coronaviruses are a diverse family of viruses that cause a range of disease in humans and animals, and there are currently no approved coronavirus vaccines or therapeutics. In January 2020, a novel coronavirus, SARS-CoV-2, was identified as the causative agent of an outbreak of viral pneumonia centered around Wuhan, Hubei Province, China. Current information regarding confirmed cases is changing daily and can be found on the Centers for Disease Control and Prevention website (<https://www.cdc.gov/coronavirus/index.html>) and through other sources. Transmission characteristics and the associated morbidity and mortality are not completely understood, but there is clear evidence of human-to-human transmission. Many other aspects of viral pathogenesis, natural history, and host range are poorly understood. Given this, there is an urgent public health need to better understand SARS-CoV-2, particularly to improve the predictive quality of existing models of spread, diagnostics for measurement of transmission, susceptibility and recovery, and development of therapeutic interventions.*

*NIGMS will accept the submission of applications for Competitive Revisions to active grants to address only the following research areas of interest:*

*Incorporation of data related to SARS-CoV-2 into ongoing research efforts to develop predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants).*

*Repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection (SBIR/STTR grants only).*

*Rapid development of potential therapeutic agents for COVID-19 (SBIR/STTR only).*



Applications that are not responsive to the above research areas of interest will be withdrawn without review.

<https://grants.nih.gov/grants/guide/notice-files/NOT-GM-20-025.html>

**Department of Health and Human Services - National Institutes of Health - Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)**

**Proposal Due Date:** Open dates may vary by awarding IC.  
**See Emergency Notice of Special Interest (NOSI) for applicable Application Due Dates**  
**Funding Opportunity Number:** PA-20-135

*Purpose: The National Institutes of Health (NIH) hereby notify the applicant community that funds may be available for applications based on a presidentially declared disaster under the Stafford Act, a public health emergency declared by the Secretary, HHS, or other local, regional or national disaster. Applications in response to Emergency Notices of Special Interest (NOSIs) will be routed directly to the NIH awarding component signed on to the Emergency NOSI.*

<https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html>

**Department of Health and Human Services - National Institutes of Health - National Heart, Lung, and Blood Institute - Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)**

**Proposal Due Date:** October 6, 2020  
**Funding Opportunity Number:** NOT-HL-20-757

*Purpose: To better understand the host response, associated HLB disease, impact on transfusion safety, and short- and long-term clinical outcomes of individuals infected with SARS-CoV-2, the NHLBI encourages the submission of applications for Administrative Supplements and Competitive Revisions to active NHLBI grants to support research on SARS-CoV-2 and HLB COVID-19 disease. Of particular interest are studies that take advantage of human research or unique model systems to study the consequences of SARS-CoV-2 infection. Supported research is expected to inform future efforts to diagnose, prevent, mitigate, or treat this viral infection and associated HLB manifestations.*

*Possible research interests include but are not limited to the following:*

*Host factors, including the microbiome or existing cardiac, respiratory, or hematologic conditions, that predispose persons to acquire SARS-CoV-2 or to develop severe COVID-19 disease, or that confer resistance to severe disease as in infants and young children*

*Manifestations, complications, and long-term consequences of SARS-CoV-2 infection, including identification of predictive biomarkers derived from imaging, clinical data, and biospecimens collected across organ systems*

*Time course and features of virus-host interactions, including the impact of SARS-CoV-2 infection on innate and adaptive immune responses*

*Prevalence and mechanisms of lung and cardiac injury with SARS-CoV-2 infection*

*Host factors and biological pathways that impact recovery and repair of the cardiopulmonary and vascular systems after SARS-CoV-2 infection*

*Development of animal or in vitro models of SARS-CoV-2 infection suitable for pathogenesis and therapeutic studies or transfusion transmission experiments such as, but not limited to, macaque and ACE-2 receptor murine models*

*Use of artificial intelligence or machine learning approaches to understand the biological pathways of COVID-19 disease, its comorbidities, and potential prevention strategies*

*Prevalence of RNAemia in symptomatic and asymptomatic people found to test positive for SARS-CoV-2 using respiratory tract samples*

*Dynamics of SARS-CoV-2 viremia and antibody response, and implications on screening and diagnostic assay development*

*Development of GMP quality hyper immune globulin from convalescent plasma collected from patients who have recovered from documented SARS-CoV-2 infection*

*Development and testing of strategies at the healthcare system level to address barriers and facilitators in the treatment of high-risk populations, particularly rural residents and underserved individuals*

*Supplementary funds may be used for the collection of blood or lung samples from human cohorts of individuals with COVID-19 or evidence of SARS-CoV-2 infection or controls, and/or development of novel model systems to expose animals and cells to SARS-CoV-2.*

*Applications in response to this NOSI must be submitted using one of the following target opportunities or subsequent reissued equivalent.*

*PA-18-591 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)*

*PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)*

<https://grants.nih.gov/grants/guide/notice-files/NOT-HL-20-757.html>

**Department of Health and Human Services - National Institutes of Health - National Institute on Drug Abuse - Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus**

**Proposal Due Date:**  
**rolling basis through March 31, 2021**

**Applications will be accepted on a**

**Funding Opportunity Number:**

**NOT-DA-20-047**

*Purpose: In order to rapidly improve our understanding of the risks, prevalence, and available control measures for 2019-nCoV in substance using or HIV-affected populations, NIDA is encouraging the submission of applications for Competitive Revisions to active grants to address the following research areas of interest:*

*Research to determine whether substance use (especially smoking tobacco or marijuana, vaping, opioids and other drug use) is a risk factor for the onset and progression of COVID-19.*

*Research on how HIV among persons who use substances may impact the onset and progression of COVID-19.*

*Research to understand system-level responses to COVID-19 prevention and risk mitigation in secure settings such as prisons and jails, with a particular emphasis on detainees with substance use disorder (SUD). For example:*

*Interactions of COVID-19 treatment with SUD treatments, including medications for opioid use disorders*

*Strategies for integrating COVID-19 and other infectious disease screening, prevention, and treatment protocols with SUD treatment and other health services.*

*Research to understand the respiratory effects of SARS-CoV-2 infection among individuals with substance use disorders (SUD); in particular those with nicotine, marijuana, opioid, and methamphetamine use disorders.*

*Research to understand how the respiratory effects of COVID-19 influences the rate of opioid overdoses both in pain patients as well as patients with an opioid use disorders and also to assess how it influences the outcomes for naloxone interventions for overdose reversal*

*Research to develop therapeutic approaches for comorbid SARS-CoV-2 infection and SUDs.*

*Research to evaluate drug-drug interaction of medications to treat SARS-CoV-2 and substances of abuse or medications to treat SUDs.*

*Research to understand system- or organizational-level responses to identify, prevent, or mitigate the impact of COVID-19 in service settings that serve vulnerable populations, including people who are homeless or unstably housed.*

*Research to understand and mitigate the impact of COVID-19 in methadone treatment programs and syringe exchange services.*

*Research on how potential overcrowding of emergency departments and health services will impact the treatment of opioid overdoses and of opioid use disorder*

*Research using ongoing studies to understand the broad impacts of COVID-19 (e.g., school closures, food insecurity, anxiety, social isolation, family loss) on neurodevelopment, substance use, substance use disorders, and access to addiction treatment.*

*PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional) is intended to provide funds for NIH grantees applying to expand the scope of their active grant.*

*PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) is intended to provide funds for NIH grantees where the work proposed in the supplement is fully within the scope of the ongoing grant.*

*The funding instrument, or activity code, will be the same as the parent award.*

<https://grants.nih.gov/grants/guide/notice-files/NOT-DA-20-047.html>

**Department of Health and Human Services - Office of Assistant Secretary for Preparedness and Response - Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)**

**White Paper Due Date:**

**October 31, 2020**

**Funding Opportunity Number:**

**BAA-18-100-SOL-00003 (BARDABAA)**

*Purpose: We appreciate your interest in partnering with BARDA. Due to the COVID-19 response, any white papers or full proposals submissions, other than those that are in support of COVID-19, will be put into a queue. Once the response to COVID-19 has subsided, we will resume normal review of submissions for other research areas of interests. BARDA will not be able to meet the timelines highlighted in the Broad Agency Announcement. Thank you for understanding this unprecedented response and delays that will occur.*

*The latest BARDA Broad Agency Announcement (BAA) is amendment 14 posted on March 9, 2020.*

*Note: COVID-19 response related Areas of Interest includes:*

*AOI 7.7.1 Diagnostic assay for human coronavirus using existing FDA-cleared platforms*

*AOI 7.7.2 Point-of-care diagnostic assay for detection of SARS-CoV-2 virus*

*AOI 7.7.3 Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection)*

*AOI 8.3 COVID-19 Vaccine*

*AOI 9.2 COVID-19 Therapeutics*

*AOI 9.3 Immunomodulators or therapeutics targeting lung repair*

*AOI 9.5 Pre-exposure and post-exposure prophylaxis*

*AOI 10 Respiratory protective devices*

*AOI 11 Ventilators*

*AOI 17 Advanced Manufacturing Technologies*

<https://beta.sam.gov/opp/1b46a4169fcb4902b9c4fcbb5bf981f7/view>

**Department of Health and Human Services - Office of Assistant Secretary for Preparedness and Response - BARDA's Division of Research, Innovation & Ventures (DRIVE) Easy Broad Agency Announcement**

**White Paper Due Date:**

**June 30, 2020**

**Funding Opportunity Number:**

**BAA-20-100-SOL-0002**

*Purpose: Under these Special Instructions 004, BARDA is now seeking abstract submissions for the following:*

*AOI #4.1-A: Molecular Diagnostic Assay for SARS-CoV-2 virus on existing FDAcleared platform*

*The development and Emergency Use Authorization (EUA) of an in vitro diagnostic assay for the detection of SARS-CoV-2 (2019-nCoV) RNA in clinical specimens, including upper (e.g., nasopharyngeal and oropharyngeal swabs, nasopharyngeal wash/aspirate, or nasal aspirate) and lower (e.g., bronchoalveolar lavage, tracheal aspirate, or sputum) respiratory tract specimens. The assay must be developed for use with an existing FDA-cleared molecular platform that is currently widely placed in U.S. healthcare settings. Preference will be given to respondents who present a viable plan that achieves an EUA submission milestone within 12 weeks of award. As part of the abstract submission, respondents should describe the current development status of their SARS-CoV-2 (2019-nCoV) assay, including in silico analysis of targets, access to validation materials to support EUA submission, and contacts with the FDA. Priority will be given to products manufactured in the United States.*

*AOI #4.1-B: Point-of-Care Diagnostic Assay for detection of SARS-CoV-2 virus*

*The development and Emergency Use Authorization (EUA) of an in vitro diagnostic test for the detection of SARS-CoV-2 (i.e., virus, viral RNA, or viral antigens) in respiratory specimens that has a small footprint (e.g., hand-held), is easy to use at the point of care (i.e., suitable for use in CLIA-waived settings) and produces results in less than 30 minutes (less than 15 minutes preferred). While there is no minimum Technology Readiness Level (TRL) required, Respondents should describe the platform, proposed detection targets, development status of the test, information to support clinical utility claims, and proposed plan to achieve EUA submission. Priority will be given to products manufactured in the United States.*

*AOI #4.1-C: Diagnostic Assay for detection of COVID-19 disease*

*The development and Emergency Use Authorization (EUA) of an in vitro diagnostic test for COVID-19 disease that has a small footprint (e.g., hand-held) and is easy to use at the point of care (i.e., suitable for use in CLIA-waived settings). Assays should detect host or pathogen biomarkers specific for COVID-19 disease in noninvasive specimens that can be easily collected in CLIA-waived settings, and provide results in less than 30 minutes (less than 15 minutes preferred). While there is no minimum Technology Readiness Level (TRL) required, Respondents should describe the platform, proposed detection targets, development status of the test, information to support clinical utility claims, and proposed plan to achieve EUA submission. Priority will be given to products manufactured in the United States.*

*AOI #4.3: COVID-19 Vaccine*

*The development of “ready to use”, rapid response platform technologies, alternative vaccine administration/delivery, and adjuvants for application to the production of COVID-19 vaccines on an accelerated timeline. Priority given to platforms that offer an integrated approach to the full spectrum of vaccine development; from creation of candidate vaccines through testing, selection and regulatory approval, to full-scale manufacturing capability with the fewest adjustments and refinements necessary for a vaccine for COVID-19. Priority will be given to products manufactured in the United States.*

*AOI #4.4: Advanced Manufacturing Technologies*

*The development and demonstration of innovations and enhancements to manufacturing platforms to support the development of necessary medical countermeasures including vaccines and therapeutics in prevention, preparation, and response to COVID-19. The purpose of the innovations and enhancement to advanced manufacturing technologies may include, but are not limited to, improving pharmaceutical*

*quality, rapidly scaling manufacturing capabilities, shortening supply chains, increasing manufacturing resilience to disruption, accelerating availability of emerging therapies/vaccines, or reducing the risk of pharmaceutical shortages. Advanced manufacturing technologies may include, but are not limited to, continuous manufacturing and additive manufacturing (including 3D printing). Priority will be given to products manufactured in the United States.*

<https://beta.sam.gov/opp/f922eb52cec446c5875811752bf2d34c/view>

## **Department of Health and Human Services - Office of Assistant Secretary for Preparedness and Response - REQUEST A USG CORONAWATCH MEETING**

*Purpose: The U.S. government is providing a portal for the 2019 novel coronavirus (COVID-19) medical countermeasures task force as a single point of entry for the submission of market research packages and meeting requests from interested stakeholders.*

*The U.S. government, in response to the COVID-19 outbreak, seeks information from stakeholders on available medical countermeasures in development. We are particularly interested in products and technologies that have progressed into or beyond non-clinical trials, have established large-scale cGMP manufacturing capability, or utilize an approved platform. Information regarding diagnostics, therapeutics, vaccines, and other products or technologies relevant to addressing this outbreak are sought.*

*The goals of BARDA's TechWatch program are outreach to stakeholders across the medical countermeasure enterprise and engagement with them through meetings to discuss their product candidates and technologies and their possible alignment with BARDA's mission. In order to meet this goal, BARDA developed a web-based infrastructure for organizing such meetings. Organizations can initiate the process of arranging a meeting by providing information and requesting BARDA TechWatch meetings via an online form, either at BARDA's invitation or on their own initiative. BARDA TechWatch meetings typically are one-hour, seminar-style meetings with appropriate Program and Technical staff, either virtually or at BARDA's D.C. offices. BARDA TechWatch meetings are informational in nature and not part of the contracting process, but the information exchanged may inform BARDA strategies and the engagement may help organizations better understand BARDA's priorities and be more responsive to its solicitations.*

*At this time, we ask for a brief description of your product or technology, accompanied by a slide deck, manuscript, publications, or other non-confidential information of your choosing. Please note that while we will use any information you present as market research, submission is no guarantee of a meeting or funding and your submission will be shared across U.S. Government agencies involved in COVID-19 medical countermeasure research and development. Only U.S. government officials are invited to join a CoronaWatch meeting, and are bound by law to maintain confidentiality of what is presented and discussed.*

*Ideal technologies and products would (but are not required to) be:*

- Relevant to the U.S. government COVID-19 medical countermeasure research and development efforts and/or Emerging Infectious Disease rapid response capabilities
- Utilize an already-approved platform, have non-clinical data suggesting efficacy, and/or have significant manufacturing capability
- Fully owned or licensed by your organization (you have full IP rights and/or freedom to operate)

<https://www.medicalcountermeasures.gov/Request-BARDA-TechWatch-Meeting>

## **Medical Supplies, Medicine, Services and Equipment**

**Department of Defense – Department of the Air Force – Commercial Solution Opening  
- CSO\_COVID\_19 Response**

**Proposal Due Date:**

**September 30, 2020**

**Expected Number of Awards:**

**Estimated Total Program Funding:**

**Award Ceiling:**

**Award Floor:**

**Funding Opportunity Number:**

**FA300220S0002**

***Purpose:** The Department of the Air Force (DAF) has been tasked to address mission needs in response to the national crisis caused by the COVID-19 pandemic. The Air Force Senior Acquisition Executive (SAE) established the Department of the Air Force Acquisition COVID-19 Task Force (DAF ACT) across the acquisition enterprise (i) to execute all requirements from the Office of the Under Secretary of Defense for Acquisition and Sustainment Joint Acquisition Task Force, (JATF) and (ii) to collect and consolidate funding requests needed to recover programs from COVID-19 impacts. The DAF ACT contains four primary lines of effort (LOE's): (1) Relief for external assistance requirements; (2) Resilience for Defense Industrial Base Efforts; (3) Recovery for consolidating funding requests that minimize program impacts; and (4) Rapid for solicitation and execution of large-scale rapid small business contracts across all lines of effort.*

### **MISSION FOCUS AREAS**

*I. Combating the Spread (predictive analytics, next hotspot, threat to current activities, decision support, etc.)*

*II. Welfare of Citizens (effects to transportation, movement of people and goods, education and development, physical training, regular HR functions, job transition, etc.)*

*III. Readiness (continuing operations through the outbreak, coordinating with allies and partners, continuing long term projects, etc.)*

*IV. Logistics (security and protection, supply chain protection and assessment, etc.)*

*V. Industrial Base Impacts (impacts on small businesses, payments, contracts, large system programs, protection and expansion of critical assets, etc.)*

*VI. Medical (telehealth, medical capacity and sustainment, medical supplies and equipment, etc.)*



VII. Other - Any solution/proposal that is not covered by the above topic areas but support the national response to the COVID-19 pandemic

**Contact:** Jessica.Steinhoff, Maj, USAF [jess.steinhoff@afwerx.af.mil](mailto:jess.steinhoff@afwerx.af.mil)

<https://beta.sam.gov/opp/f48d23af514f494f819f0c33e9f40e17/view>

**Department of Defense – Department of the Army - State of Minnesota - Medical PPE for COVID 19**

**Proposal Due Date:**

**April 21, 2020**

**Expected Number of Awards:**

**Estimated Total Program Funding:**

**Award Ceiling:**

**Award Floor:**

**Funding Opportunity Number:**

**Y6AAA-20-Q-0004**

**Purpose:** *The State of Minnesota seeks to procure the below items as soon as possible and at fair and reasonable prices. All offered items must meet the current CDC Guidelines. Contractors do not need to offer all items; partial proposals may be submitted. Shipments are targeted to begin within 7 days of this posting (or sooner) and with continued weekly deliveries through the end of June. Additional quantities may be requested beyond June depending on the State of Minnesota COVID response guidance. The State of Minnesota reserves the right to issue multiple awards based on the offers received. The items listed below are currently the only items being sought. Use the attached form for submitting proposals by completing the applicable red highlighted areas.*

*Nitrile Medical Grade Exam Disposable Gloves. Each of these gloves need to have a thickness greater than 3.5 millimeters. The State of Minnesota is NOT considering Vinyl or Latex Medical Grade Exam Disposable Gloves at this time. The total number of gloves is to be counted by each glove and not by the pair. These quantity of Nitrile Medical Grade Exam Disposable Gloves is 9,000,000 million each with the following breakdown of the sizes, where applicable: XS: 5%, SM: 10%, MD: 35%, LG: 35%, XL: 10%, XXL: 5%. An estimated total quantity of 60,000,000 million gloves are expected to be purchased over the next three months: April, May and June.*

*3-Ply Disposable Face Masks at a quantity of 1,330,000 each, broken down by sizes as follows, where applicable: XS: 5%, SM: 10%, MD: 60%, LG: 20%, XL: 5%. Similar quantities are expected to be purchased over the next three months: April, May and June.*

*N95 Masks at a quantity of 1,330,000 each, broken down by sizes as follows, where applicable: XS: 5%, SM: 10%, MD: 60%, LG: 20%, XL: 5%. Similar quantities are expected to be purchased over the next three months: April, May and June.*

*Face Shields at a quantity of 50,000 each, broken down by sizes as follows, where applicable: XS: 5%, SM: 10%, MD: 60%, LG: 20%, XL: 5%. Similar quantities are expected to be purchased over the next three months: April, May and June.*

*Powered Air Purifying Respirator (PAPR) Masks at a quantity of 50,000 each, broken down by sizes as follows, where applicable: SM 10% ; SM/MD 20% ; MD 40% ; MD/LG 20% ; LG 10%. Similar quantities are expected to be purchased over the next three months: April, May and June.*

*BiPap Masks: at a quantity of 50,000 each, broken down by sizes as follows, where applicable: XS: 5%, SM: 10%, MD: 60%, LG: 20%, XL: 5%. Similar quantities are expected to be purchased over the next three months: April, May and June.*

*Two Piece Impervious Gowns (5,000,000 quantity each) + Impervious Hood (5,000,000 quantity each); OR Impervious Coveralls (Gown Hood Combination 5,000,000 quantity), broken down by sizes as follows, where applicable: XS: 5% SM: 10% MD: 60% LG: 20% XL: 5% . Similar quantities are expected to be purchased over the next three months: April, May and June.*

*Two Piece Disposable/Washable Gowns (1,330,000 quantity each) + Washable/Disposable Hood (1,330,000 quantity each) OR Washable/Disposable Coveralls (Gown Hood Combination 1,330,000 quantity) broken down by sizes as follows, where applicable: XS: 5% SM: 10% MD: 60% LG: 20% XL: 5%. Similar quantities are expected to be purchased over the next three months: April, May and June.*

*Safety Goggles at a quantity of 25,000 broken down by sizes as follows, where applicable: XS: 5% SM: 10% MD: 60% LG: 20% XL: 5%. Similar quantities are expected to be purchased over the next three months: April, May and June.*

*Shoe Covers at a quantity of 1,670,000 broken down by sizes as follows, where applicable: XS: 5% SM: 10% MD: 60% LG: 20% XL: 5%. Similar quantities are expected to be purchased over the next three months: April, May and June.*

*PAPR Hoods at a quantity of 100,000 broken down by sizes as follows, where applicable: XS: 5% SM: 10% MD: 60% LG: 20% XL: 5%. Similar quantities are expected to be purchased over the next three months: April, May and June.*

*Vendors can expect a Purchase Order from the State of Minnesota to guarantee payment for immediate delivery of supplies. Vendors must register in the State of Minnesota StateWide Integrated Financial Tools (SWIFT) online system: <https://mn.gov/mmb/accounting/swift/vendor-resources/> to receive payment. Shipments will be delivered to the Minnesota Department of Health warehouse at 345 Plato Blvd NE, Saint Paul, MN 55107.*

*<https://beta.sam.gov/opp/a5b0f1c63f2d4a00b18242a0264ebb5a/view>*

**Department of Defense – Department of the Navy - COVID-19 Sources Sought for PPE  
Response Date: April 15, 2020**

**Funding Opportunity Number:**

**N6883620X0001**

**Purpose:** The NAVSUP Fleet Logistics Center Jacksonville (FLCJ) is conducting market research to determine industry capabilities for providing Personal Protective Equipment (PPE) against viral contamination, specifically COVID-19. This is a Request for Information only and not a solicitation for award. NAVSUP FLCJ understands this is a fluid situation where the landscape of availability of critical items is constantly changing. The primary purpose of this announcement is to identify potential sources, product offerings, availability and/or challenges to procuring and obtaining such items to rapidly meet emerging requirements. Therefore, to the extent practical, additional market research may be conducted prior to posting any solicitation to capture the snapshot of the availability at that specific point in time. NAVSUP FLCJ urges those companies that can provide the following category of items to respond even after the initial response due date of April 15, 2020, 4:00 PM Eastern.

The categories are not an all-inclusive list. NAVSUP FLCJ welcomes industry to identify alternatives or identify additional PPE items necessary to protect against viral contamination of COVID-19.

NAVSUP FLCJ is seeking to identify vendors capable of providing the requirements listed below. This is not a formal solicitation or an award. The government reserves the right to determine whether to compete, award some, all or nothing as a result of responses to this notice.

Any firm who believes they can provide the above requirements in whole or in part, should respond to this notice with written notification to the point of contact below.

NAVSUP FLCJ is also, asking industry to identify/recommend specific products available or specific products that could be available in the near term that can meet the requirements of PPE to protect against viral contamination of the COVID-19 virus.

<https://beta.sam.gov/opp/eace2addfa4a4c208b2050e9326b37f3/view>

**Department of Defense – Department of the Navy - Medical Supplies and Personal Protective Equipment: COVID 19 Response**

**Response Date:**

**April 17, 2020**

**Funding Opportunity Number:**

**M2710020Q5401**

**Purpose:** This is a combined synopsis/solicitation for Medical Supplies and Personal protective equipment prepared in accordance with the Federal Acquisition Regulation (FAR) Part 12.6, as supplemented with additional information included in this notice.

This announcement constitute the only solicitation, proposal (quote) are being requested and a written solicitation will not be issued. Contract award resulting will be a Firm-Fixed Price (FFP) Contract.

This procurement is 100% small business set aside. All responsible small business sources may submit a response which, if timely received, will be considered by the agency.

*Partial quotes will be accepted and the award will be furnish to multiple vendors being acceptable.*

*This is a brand name or equal requirement, vendor must show how their quotes meets or exceed the characteristics of what is requested in the solicitation.*

<https://beta.sam.gov/opp/23a39a9e90a1485e8c4c3ddca3bb92b9/view>

**Department of Defense – National Geospatial-Intelligence Agency (NGA) - COVID 19 - Seeking potential sources for Surgical Masks and Sanitizing Wipes**

**Response Date:**

**April 9, 2020**

**Funding Opportunity Number:**

**HM157520R5556**

***Purpose:** The National Geospatial-Intelligence Agency (NGA) is seeking sources from which to procure surgical face masks and sanitizing wipes necessary for our workforce during the Covid-19 pandemic. This posting is seeking responses from vendors capable of providing surgical masks and sanitizing wipes for use at NGA's 3 main campuses in Springfield, VA, St. Louis, MO, and Arnold, MO.*

*The NGA is a combat support agency under the United States Department of Defense and a member of the United States Intelligence Community, with the primary mission of collecting, analyzing, and distributing geospatial intelligence in support of national security. With a 24-7-365 mission required to ensure the safety and interests of the United States, NGA's facilities must remain accessible for mission critical work during this pandemic. As such, sources for surgical masks and sanitizing wipes may become necessary to ensure continuity of operations.*

*Delivery dates for these items are not currently identified but may be needed in short order to all or some combination of the NGA facilities in Springfield, VA, St. Louis, MO, and Arnold, MO. Additional NGA facilities might later be identified as determined by the Agency.*

*Responses to this notice should be directed to Patrick Fallon, Contracting Officer, [patrick.j.fallon@nga.mil](mailto:patrick.j.fallon@nga.mil) and Jeffrey Teague, Contracting Officer, [jeffrey.h.teague@nga.mil](mailto:jeffrey.h.teague@nga.mil). Please include in your responses, potential quantities and specifications for available sanitizing wipes and surgical masks that your company has available to fulfill potential future NGA requirements. If physical locations are limiting to your company, the NGA also request that you identify which NGA facilities that you can fulfill potential requirements.*

<https://beta.sam.gov/opp/af0e75f552eb402590a9813f7d6bb8d0/view>

**Department of Defense – Defense Logistics Agency - Request for Information pertaining to Medical PPE in response to COVID-19 \*\***

**Response Date:**

**April 15, 2020**

**Funding Opportunity Number:**

**SPE2DS-20-R-COVID19**

**Purpose:** Defense Logistics Agency (DLA) Troop Support Medical Directorate is conducting market research to determine industry capabilities for providing Medical Personal Protective Equipment (PPE) against COVID-19. This is a Request for Information only and not a solicitation for award. DLA understands this is a fluid situation where the landscape of availability is constantly changing. The primary purpose of this announcement is to identify potential sources, product offerings, availability and/or challenges to procuring and obtaining such items to rapidly meet emerging requirements. Therefore, to the extent practical, additional market research may be conducted prior to posting any solicitation to capture the snapshot of the availability at that specific point in time. DLA urges those companies that can provide the following category of items to respond even after the initial response due date of Wednesday, 15 April 2020, 6:00 PM.

**CATEGORIES:**

- (1) Medical Examination Gloves.
- (2) Medical Aprons
- (3) Medical Face Masks (N95 Respirator)
- (4) Medical Face Shields
- (5) Hand Sanitizer
- (6) Surgical Masks
- (7) Swab Viral Transport Kit
- (8) Viral Transport Swabs
- (9) SWAB Nasopharyngeal
- (10) Medical Thermometers

DLA is asking the Industry to:

Identify/recommend specific products available or specific products that could be available in the near term that can meet the requirements of PPE to protect against the COVID-19 virus.

Probable and possible delivery points for noted medical material: New Cumberland, PA; Fort Stewart, GA; Ft. Drum, NY, Tracy, CA

<https://beta.sam.gov/opp/1901f1a3c4974a5e8d907d4558c8d377/view>

**Department of Health and Human Services - Office of Assistant Secretary for Preparedness and Response - Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)**

**White Paper Due Date:**

**April 30, 2020**

**Funding Opportunity Number:**

**BAA-18-100-SOL-00003 (BARDABAA)**

*Purpose: We appreciate your interest in partnering with BARDA. Due to the COVID-19 response, any white papers or full proposals submissions, other than those that are in support of COVID-19, will be put into a queue. Once the response to COVID-19 has subsided, we will resume normal review of submissions for other research areas of interests. BARDA will not be able to meet the timelines*

*highlighted in the Broad Agency Announcement. Thank you for understanding this unprecedented response and delays that will occur.*

*The latest BARDA Broad Agency Announcement (BAA) is amendment 14 posted on March 9, 2020.*

*Note: COVID-19 response related Areas of Interest includes:*

*AOI 7.7.1 Diagnostic assay for human coronavirus using existing FDA-cleared platforms*

*AOI 7.7.2 Point-of-care diagnostic assay for detection of SARS-CoV-2 virus*

*AOI 7.7.3 Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection)*

*AOI 8.3 COVID-19 Vaccine*

*AOI 9.2 COVID-19 Therapeutics*

*AOI 9.3 Immunomodulators or therapeutics targeting lung repair*

*AOI 9.5 Pre-exposure and post-exposure prophylaxis*

*AOI 10 Respiratory protective devices*

*AOI 11 Ventilators*

*AOI 17 Advanced Manufacturing Technologies*

<https://beta.sam.gov/opp/1b46a4169fcb4902b9c4fcb5bf981f7/view>

**Department of Health and Human Services - Office of the Assistant Secretary for Financial Resources (ASFR) - COVID-19 Response: Supplies and Services**

**Proposal Due Date:**

**April 30, 2020**

**Funding Opportunity Number:**

**HHS\_ASFR\_COVID-19\_Response-**

**Supplies\_and\_Services**

*Purpose: The Department of Health and Human Services (HHS) has a requirement to provide medical and pharmaceutical related material and services to various locations across the US during this public health emergency and response effort. The Department anticipates receiving Mission Assignments generated from within and outside HHS to purchase and distribute required services, products and equipment. Any delay in providing critical medical supplies, services and equipment could cause irreparable harm and put American citizens at an increased risk of transmission and exposure.*

*Every effort must be made to provide needed products and services in the most expedient manner. HHS is working in tandem with other Federal Agencies which, among others, are providing disaster medical assistance teams to provide medical relief and assistance to areas impacted by COVID-19. In support of these efforts, HHS has an urgent need to obtain supplies and services to ensure the delivery of potentially lifesaving and preventative medical supplies and services in support of the response to the COVID-19 pandemic.*

*The listed Product Service Code, General Health Care Services (Q201), is not the only PSC that applies to this notice. PSC code Q201 was listed because of the data field requirements for posting notices on beta.sam.gov AND as a general point of reference.*



*Research & development (R&D)*

*R & D support services*

*Support services (non-R&D)*

*Supplies/equipment*

*Information technology (IT)*

*Construction*

*Architect-engineer (A & E) services*

*Design-build*

*Other (specify): Additional requirements as needed to support recovery efforts related to this national emergency*

Contact: Michael McFarland [michael.mcfarland@hhs.gov](mailto:michael.mcfarland@hhs.gov) Phone Number 202-868-9447

<https://beta.sam.gov/opp/734a1c5310944252b9e0348272282be3/view>

## **Department of Health and Human Services – Food and Drug Administration - Emergency Use Authorization Declaration**

**Effective date:**

**February 4, 2020**

*Purpose: Under section 564 of the FD&C Act, 21 U.S.C. 360bbb-3, the Commissioner of the Food and Drug Administration (FDA), acting under delegated authority from the Secretary of HHS, may issue an Emergency Use Authorization (EUA) authorizing (1) the emergency use of an unapproved drug, an unapproved or uncleared device, or an unlicensed biological product; or (2) an unapproved use of an approved drug, approved or cleared device, or licensed biological product. Before an EUA may be issued, the Secretary of HHS must declare that circumstances exist justifying the authorization based on one of four determinations: (1) A determination by the Secretary of Homeland Security that there is a domestic emergency, or a significant potential for a domestic emergency, involving a heightened risk of attack with a, chemical, biological, radiological, or nuclear (“CBRN”) agent or agents; (2) the identification of a material threat by the Secretary of Homeland Security pursuant to section 319F-2 of the Public Health Service (PHS) Act sufficient to affect national security or the health and security of United States citizens living abroad; (3) a determination by the Secretary of Defense that there is a military emergency, or a significant potential for a military emergency, involving a heightened risk to United States military forces, including personnel operating under the authority of title 10 or title 50, of attack with (i) a biological, chemical, radiological, or nuclear agent or agents; or (ii) an agent or agents that may cause, or are otherwise associated with, an imminently life-threatening and specific risk to United States military forces; or (4) a determination by the Secretary that there is a public health emergency, or a significant potential for a public health emergency, that affects, or has a significant potential to affect, national security or the health and security of United States citizens living abroad, and that involves a CBRN agent or agents, or a disease or condition that may be attributable to such agent or agents.*

<https://www.federalregister.gov/documents/2020/03/27/2020-06541/emergency-use-authorization-declaration>

**Department of Homeland Security – Federal Emergency Management Agency - COVID-19 PPE and Medical Supplies**

**Response Date:** September 25, 2020  
**Funding Opportunity Number:** 70FA2020R00000011

*Purpose: This is a combined synopsis/solicitation for commercial items under FAR part 12 prepared in accordance with the format in subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued.*

*ii. This is a standing solicitation issued under unusual and compelling urgency. The Government contemplates making separate, single awards to multiple vendors for the commercial supplies offered in response to this solicitation. The Government may make awards of IDIQs and/or Direct Contracts (under FAR Part 12), Purchase Orders (under FAR Parts 8 and 13), and Blanket Purchase Agreements under FAR Parts 8 and 13 for the supplies listed in Attachments A through E. This solicitation may be amended to provide additional detailed specifications for each item included on the attachment. All products delivered shall be in accordance with FDA, HHS, CDC regulations and guidelines. Products will be subject to Government testing.*

<https://beta.sam.gov/opp/8b6e60ecef8a480793b81c1225daf09a/view>

**Department of Homeland Security – Federal Emergency Management Agency - Federal Emergency Management Agency - RFI FEMA REGION VI COVID-19 PERSONAL PROTECTIVE EQUIPMENT**

**Response Date:** May 4, 2020  
**Expected Number of Awards:**  
**Funding Opportunity Number:** RFI70FBR620Q00000001

*Purpose: The Federal Emergency Management Agency (FEMA) Region VI is seeking information related on the ability of interested contractors/vendors to provide medical personal protective equipment as stated in the attached request for information (RFI).*

*The U.S. Government is interested in establishing multiple awards for immediate purchases of Face Masks, Gowns / Overalls, Gloves, and Face Shields / Eye Protection used in healthcare settings as described below. This will enable the United States to ensure sufficient availability of such items during national emergencies and/or pandemic events. The Government is concerned about the risks of disruption of any manufacturing facilities or supply chains located outside of the United States. Thus, offerors are advised to pay special attention to the instructions regarding manufacturing capability and/or supply chains located outside of the United States as well as the evaluation criteria related to*

*manufacturing capability and foreign supply chains. The Government is concerned about the risks related to excessive pricing of critical PPE and intends only to acquire PPE at prices that it can determine are fair and reasonable. Thus, offerors are advised to pay special attention to the instructions regarding pricing.*

<https://beta.sam.gov/opp/d18f58a4d2084e9e8b12700abc1becb9/view>

### **Department of Veterans Affairs 8340--Decontamination Tents & A/C Units**

**Proposal Due Date:** April 9, 2020  
**Funding Opportunity Number:** 36C24820Q0628

*Purpose: The North Florida South Georgia Veterans Health System has an urgent need for four (4) inflatable decontamination tents and six (6) portable air conditioners that are compatible with the tents for the Lake City VA Medical Center, located at 619 S. Marion Ave, Lake City, Florida.*

*Currently, the nation is combating the COVID-19 Coronavirus, which has been declared a national emergency. The need for this equipment is to assist the first responders and is vital in this effort to control the spread of the virus. The North Florida Incident Command and Emergency Management have a bona-fide need for these inflatable decontamination tents and accessories to run them adequately.*

*The tents will be used for the expansion of the emergency department to prepare for and to combat the spread of the COVID-19 virus. These tents will be instrumental in the control of contamination of patients and the decontamination of staff.*

<https://beta.sam.gov/opp/de6954b42b664acc84c22bd2f49b482f/view>

### **Department of Veterans Affairs - 6515--COVID-19 Request for Information Suitable Substitutions for VISN Items - GLOVE, EXAM, NITRILE - RFI**

**Proposal Due Date:** April 10, 2020  
**Funding Opportunity Number:** 36C26320Q0370

*Purpose: RFI out for the below Exam Gloves. We need sizes Small/Medium/Large/X-Large. Below is a clip from MEDLINE if you need specs. GLOVE,EXAM,NITRILE,SM,POWDER-FREE,NON-STER,BEADED CUFF GLOVE,EXAM,NITRILE,MED,LTX-FREE,POWDER-FREE,TEXTURED,BILAT GLOVE,EXAM,NITRILE,LG,LTX-FREE,POWDER-FREE,TEXTURED,NON-STER GLOVE,EXAM,NITRILE,XL,SYNTHETIC POWDER,TEXTURED,NON-STER*

<https://beta.sam.gov/opp/4cde252dcde3422aa50d06e712caef28/view>

**Workforce and Health Systems Research**

**Department of Health and Human Services - Agency for Healthcare Research and Quality - Notice of Intent: New Funding Opportunity Announcement to Support Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19**

**Proposal Due Date:**

**Notice of Intent**

**Funding Opportunity Number:**

**NOT-HS-20-008**

*Purpose: AHRQ intends to publish a new funding opportunity announcement using the R01 mechanism to support novel, high-impact studies evaluating health system and healthcare professional responsiveness to COVID-19. This Notice is being provided to allow potential applicants sufficient time to develop responsive applications.*

*The health systems research community should prepare to submit applications to AHRQ to fund critical research focused on evaluating topics such as innovations and challenges encountered in the rapid expansion of telemedicine in response to COVID-19, effects on quality, safety, and value of health system response to COVID-19, and the role of primary care practices and professionals during the COVID-19 epidemic. AHRQ is particularly interested in understanding how digital health innovations contributed to health system and healthcare professional innovation and challenges and solutions to meeting the needs of vulnerable populations including older adults, people living with multiple chronic conditions, rural communities, and uninsured and underinsured populations. AHRQ will encourage multimethod, rapid-cycle research with the ability to produce and disseminate findings as early as 6 months. AHRQ expects to invest up to \$5M in FY2020 funds to support this initiative and potentially more pending supplemental funding. AHRQ is working to publish the FOA in early May 2020 with submissions due in June 2020.*

*Current AHRQ grantees should also see AHRQ's Notice of Intent to allow revision supplements to existing AHRQ grants and cooperative agreements to address health system responsiveness to COVID-19.*

<https://grants.nih.gov/grants/guide/notice-files/NOT-HS-20-008.html>

**Department of Health and Human Services - Agency for Healthcare Research and Quality - Notice of Intent: Revision Supplements to Existing AHRQ Grants and Cooperative Agreements to Address Health System Responsiveness to COVID-19**

**Proposal Due Date:**

**Notice of Intent**

**Funding Opportunity Number:**

**NOT-HS-20-007**

*Purpose: AHRQ intends to publish a new funding notice allowing requests for urgent revision supplements to existing AHRQ grants and cooperative agreements to address health system responsiveness to COVID-19. AHRQ intends to allow grantees with active AHRQ research grants to submit requests for competitive revision supplements to address timely health system and healthcare*

professional response to COVID-19. Grant activity codes to be included or excluded from the funding notice will be specified in the announcement.

It is expected that competitive revision supplement requests will capitalize on the expertise of grant personnel and the institutional environment to expand the specific aims of the on-going research to develop high-impact new knowledge concerning COVID-19. Competitive revision supplements will be limited in duration (perhaps 12 months). The amount of supplemental funds that may be requested will be limited, and will be specified in the funding notice. AHRQ expects to make at least \$2.5M available to fund meritorious revision supplements in FY2020. AHRQ plans to release the supplement announcement in April 2020 with an opening date in mid-May.

Please also see AHRQ's Notice of Intent to publish a new FOA requesting new competitive applications targeting the evaluation of health system responsiveness to COVID-19.

<https://grants.nih.gov/grants/guide/notice-files/NOT-HS-20-007.html>

**Department of Health and Human Services – National Institutes of Health - National Institute of Environmental Health Sciences - Notice of Special Interest: NIEHS Worker Training Program Coronavirus and Infectious Disease Response Training (Admin Supp Clinical Trial Not Allowed)**

**Proposal Due Date:**

**April 24, 2020**

**Funding Opportunity Number:**

**NOT-ES-20-014**

*Purpose: The purpose of this supplement is to provide support for the conduct of worker-based training to prevent and reduce exposure of hospital employees, emergency first responders, and other workers who are at risk of exposure to Coronavirus through their work duties. The NIEHS Superfund Worker Training Program (WTP) will work collaboratively to develop and target safety and health training for those workers supporting the national Coronavirus response. Using our hazmat trainers' understanding of worker safety and health protection issues, knowledge of personal protective equipment (PPE) usage, and experience in training disaster workers, WTP will coordinate with the Centers for Disease Control and Prevention (CDC), the Occupational Safety and Health Administration (OSHA), and the National Institute for Occupational Safety and Health (NIOSH) to provide awardees with material to develop an evidence-based curriculum that addresses the science of Coronavirus (clinical symptoms, mode of transmission, persistence in the environment, and treatment); infection control and worker protection (isolation/quarantine and PPE); working in the contaminated environment (sampling and decontamination); and behavioral health resiliency. The funding for this supplement is provided from the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020.*

*This Notice of Special Interest (NOSI) requests applications for FY 2020 administrative supplements to provide support to conduct worker-based training to prevent and reduce exposure of hospital employees, emergency first responders, and other workers who are at risk of exposure to Coronavirus through their work duties. Under the Infectious Disease Response (IDR) program the WTP implemented an infectious disease response training for workers across sectors who may be exposed to infectious*

diseases. The program, funded under RFA-ES-15-018 began June 1, 2016, and ran through May 31, 2019 and built federal capacity for biosecurity, biopreparedness, and rapid response to emerging infectious diseases, including developing an infrastructure of trainers and organizations who can be a resource during emergencies. As of May 31, 2019, program grantees delivered approximately 1,700 courses to 36,000 workers, with more than 145,000 contact hours. In-person trainings occurred in 36 states and one territory. A Pathogen Safety Data course was created and piloted to improve workers' health literacy and empower them to perform job hazard analysis on specific pathogens allowing them to mitigate or reduce their exposure while performing their assigned duties.

<https://grants.nih.gov/grants/guide/notice-files/NOT-ES-20-014.html>

## **Other Notices**

### **Department of Defense – Defense Logistics Agency - Reporting Coronavirus Impacts To Defense Logistics Agency (DLA)**

**Response Date:** June 30, 2020  
**Funding Opportunity Number:** COVID19\_RFI\_DLA

***Purpose:** DLA has created a Request for Information (RFI) available on March 23, 2020, located at <https://www.research.net/r/DLACOV19RFI> that we are encouraging suppliers to answer. This will keep DLA informed of potential impacts to the welfare and safety of your workforce and/or overall contract performance. DLA will also use RFI responses to help assess the current status of the supplier base.*

*This Request for Information (RFI) has been issued to facilitate communication with DLA contractors that may be impacted by the novel Coronavirus, also known as COVID-19. The purpose of the RFI is to inform DLA of potential impacts that COVID-19 may have on your organization in support of the Warfighter. There are no more than 9 brief questions depending on your sequence of responses. The RFI will ask you to enter your organization's unique Commercial and Government Entity (CAGE) code. You will also be asked to provide a POC for any follow-up questions that may be asked by DLA representatives. Please access the RFI link at any time to submit an update for your organization's status, if circumstances have changed as a result of the impact of COVID-19. If you are completing the RFI for more than one CAGE code, please submit separate responses using the same RFI link and the appropriate CAGE code.*

**Contact:** N/A

<https://beta.sam.gov/opp/c0f20160b4c04cff8ccf96fc13efcf52/view>

**Department of Education - Allocations for Section 18004(a)(1) of the CARES Act \*\***



**Purpose:** The funding is the first tranche of the nearly \$31 billion of overall education aid that was included as part of the stimulus law, H.R. 748 (116)

<https://www2.ed.gov/about/offices/list/ope/allocationsforsection18004a1ofcaresact.pdf>

## **Department of Health and Human Services – Centers for Disease Control - COVID-19 Award Details For Emergency Supplemental Appropriation Funding**

*Purpose: HHS has developed a feature that allows public viewing of all COVID-19 HHS grant and cooperative agreement awards on its website at <https://taggs.hhs.gov/coronavirus>. The site is a feature of TAGGS, HHS' tracking system for these awards. The new feature provides data on awards made by all HHS awarding agencies under the supplemental appropriations funded through the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020, the Families First Coronavirus Response Act, and the CARES Act, when awards are made.*

*The site provides:*

- U.S. map detailing the amounts awarded by state,
- Graphics detailing numbers of awards, amounts awarded by agency, and awards by program (CFDA number);
- Tables, including exportable data, with awards made by HHS using these emergency supplemental appropriation funding; and
- Ability to sort tables by a variety data elements (column headers).

*Additional features are under development.*

*The HHS TAGGS website houses over 20 years of grant related data designed to foster understanding of availability, benefits, and trends in HHS financial assistance.*

<https://taggs.hhs.gov/coronavirus>

## **Department of Health and Human Services – Centers for Medicare & Medicaid Services - Medicare and Medicaid Programs; Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency – Rule**

**Effective Date: March 31, 2020**

**Comments Due Date: June 1, 2020**

*Purpose: This interim final rule with comment period (IFC) gives individuals and entities that provide services to Medicare beneficiaries needed flexibilities to respond effectively to the serious public health threats posed by the spread of the 2019 Novel Coronavirus (COVID-19). Recognizing the urgency of this situation, and understanding that some pre-existing Medicare payment rules may inhibit innovative uses of technology and capacity that might otherwise be effective in the efforts to mitigate the impact of the pandemic on Medicare beneficiaries and the American public, we are changing Medicare payment rules during the Public Health Emergency (PHE) for the COVID-19 pandemic so that physicians and other practitioners, home health and hospice providers, inpatient rehabilitation facilities, rural health clinics (RHCs), and federally qualified health centers (FQHCs) are allowed broad flexibilities to*

*furnish services using remote communications technology to avoid exposure risks to health care providers, patients, and the community. We are also altering the applicable payment policies to provide specimen collection fees for independent laboratories collecting specimens from beneficiaries who are homebound or inpatients (not in a hospital) for COVID-19 testing. We are also expanding, on an interim basis, the list of destinations for which Medicare covers ambulance transports under Medicare Part B. In addition, we are making programmatic changes to the Medicare Diabetes Prevention Program (MDPP) and the Comprehensive Care for Joint Replacement (CJR) Model in light of the PHE, and program-specific requirements for the Quality Payment Program to avoid inadvertently creating incentives to place cost considerations above patient safety. This IFC will modify the calculation of the 2021 and 2022 Part C and D Star Ratings to address the expected disruption to data collection and measure scores posed by the COVID-19 pandemic and also to avoid inadvertently creating incentives to place cost considerations above patient safety. This rule also amends the Medicaid home health regulations to allow other licensed practitioners to order home health services, for the period of this PHE for the COVID-19 pandemic in accordance with state scope of practice laws. We are also modifying our under arrangements policy during the PHE for the COVID-19 pandemic so that hospitals are allowed broader flexibilities to furnish inpatient services, including routine services outside the hospital.*

<https://www.federalregister.gov/documents/2020/04/06/2020-06990/medicare-and-medicaid-programs-policy-and-regulatory-revisions-in-response-to-the-covid-19-public>

## **Department of Health and Human Services – Food and Drug Administration - Process for Making Available Guidance Documents Related to Coronavirus Disease 2019**

*Purpose: In the Federal Register of March 25, 2020, FDA published a Notice announcing the process for making COVID-19 related guidance documents available to the public. The process is in accordance with FDA's established good guidance practices regulations and will enable FDA to more rapidly disseminate and implement agency recommendations and policies related to COVID-19.*

*As part of this process, FDA intends to periodically publish a consolidated Notice of Availability (NOA) announcing the availability of all COVID-19-related guidance documents FDA issued during the relevant period. Interested parties can access the NOAs when published in the Federal Register by clicking on the appropriate link contained in the table below listing COVID-19-related guidance documents.*

<https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-related-guidance-documents-industry-fda-staff-and-other-stakeholders>

## **Department of Health and Human Services – National Institutes of Health - NIH Late Application Policy Due to Public Health Emergency for United States for 2019 Novel Coronavirus (COVID-19)**

**Funding Opportunity Number:**

**NOT-OD-20-091**

*Purpose: NIH will be highly accommodating of late applications submitted through May 1, 2020. We anticipate, but cannot guarantee, that all late applications submitted by that date will be reviewed in the council round to which they were submitted (e.g. August or October 2020). As much as NIH would like to extend flexibility further, this rapidly evolving situation also creates multiple challenges for conducting review, and the timeline for getting review outcomes to councils (so that funding can occur) can only be delayed so long. Therefore, applicants should assume that late applications submitted after May 1 may not be reviewed until meetings for the January 2021 council round (e.g., October-November 2020).*

*NIH understands that the emergency declaration related to novel coronavirus (COVID-19) will adversely affect many NIH applicants' ability to submit applications in a timely manner.*

*Therefore, all grant applications submitted late for due dates between March 9, 2020, and May 1, 2020, will be accepted through May 1, 2020.*

*This notice applies to all relevant funding opportunity announcements, including those that indicate no late applications will be accepted. Institutions need not request advance permission to submit late due to this declared emergency and a cover letter providing a justification is not required.*

<https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-091.html>

## **Department of Housing and Urban Affairs - CPD PROGRAM FORMULA ALLOCATIONS AND CARES ACT SUPPLEMENTAL FUNDING FOR FY 2020**

*Purpose: The Fiscal Year (FY) 2020 budget for the Department of Housing and Urban Development has been enacted. These spreadsheets provide full-year allocations for the Office of Community Planning and Development's (CPD) formula programs: Community Development Block Grants (CDBG); CDBG Recovery Housing Program (RHP); HOME Investment Partnerships (HOME); Housing Opportunities for Persons with AIDS (HOPWA); Emergency Solutions Grants (ESG); and Coronavirus Aid, Relief, and Economic Security (CARES Act) supplemental funding.*

*The allocations reflect the level of funding approved for these programs in your community. The amounts also reflect approved grant reductions and include any reallocated funds for the CDBG and HOME programs. Under the CDBG program, some metropolitan cities have a joint grant agreement with an urban county to administer their CDBG grant (applicable to CARES grants as well). The urban county amounts shown in this table include the funds allocated to any metropolitan city. The metropolitan city and urban county amounts are not shown separately.*

[https://www.hud.gov/program\\_offices/comm\\_planning/budget/fy20/](https://www.hud.gov/program_offices/comm_planning/budget/fy20/)

## **National Endowment for the Arts - NEA Coronavirus Aid, Relief, and Economic Security (CARES) Act, FY2020**

**Proposal Due Date:** April 22, 2020  
**Expected Number of Awards:**  
**Estimated Total Program Funding:**  
**Award Ceiling:** \$250,000  
**Award Floor:** \$50,000  
**Funding Opportunity Number:** 020NEA01CARES60

*Purpose: The Coronavirus Aid, Relief, and Economic Security (CARES) Act recognizes that the nonprofit arts industry is an important sector of America's economy. The National Endowment for the Arts will award funds to nonprofit arts organizations across the country to help these entities and their employees endure the economic hardships caused by the forced closure of their operations due to the spread of COVID-19. As part of this important investment, the Arts Endowment has designed a plan to expedite the distribution of critical funds to the national, regional, state, and local levels to help retain as many jobs as possible, as quickly as possible. These funds are intended to help save jobs in the arts sector and keep the doors open to the thousands of organizations that add value to America's economy and the creative life of our communities.*

*This program will be carried out through one-time grants to eligible nonprofit organizations including arts organizations, local arts agencies, statewide assemblies of local arts agencies, arts service organizations, units of state or local government, federally recognized tribal communities or tribes, and a wide range of other organizations that can help advance the goals of the Arts Endowment and this program. Grants will be made either to organizations for their own operations, or to designated local arts agencies, eligible to subgrant, for subgranting programs to eligible nonprofit organizations (see "Subgranting Funds").*

*All applicants must be previous National Endowment for the Arts award recipients from the past four years (Fiscal Year 2017-2020; see "Applicant Eligibility" for more information).*

<https://www.grants.gov/web/grants/view-opportunity.html?oppld=326140>

### **National Science Foundation - Impact on Existing Deadline Dates (COVID-19)**

*Purpose: Proposers are advised that NSF will be extending the deadline date for the solicitations or Dear Colleague Letters (DCLs) listed in the table below. Additional solicitations or DCLs may be added to the list, so proposers are strongly encouraged to check NSF's website regularly. Deadlines for published program descriptions, announcements, solicitations and DCLs that do not appear on the list below remain unchanged.*

[https://www.nsf.gov/bfa/dias/policy/covid19/covid19\\_deadlines.pdf](https://www.nsf.gov/bfa/dias/policy/covid19/covid19_deadlines.pdf)

**\*\* New Opportunity since previous day.**